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Glioblastoma (GBM) is the most common malignant primary brain tumour in adults, 
with a median survival time of approximately ~15 months after diagnosis. GBM stem 
cells (GSCs) underpin GBM’s aggressiveness, resistance to radiation and 
chemotherapy, and disease recurrence. Glioblastoma stem cells (GSCs) are capable 
of tumour formation upon orthotopic transplantation into immunocompromised mice 
and share many properties of neural stem cells (NSCs). One feature common to both 
GSCs and NSCs is high expression of the transcription factor SOX2. SOX2 is known 
to be essential for GCS self-renewal. To understand further how SOX2 exerts its 
function in GSCs, the Pollard laboratory studied the interactome of SOX2. Using 
SICAP-MS – a method that looks at the on-chromatin interactors of the protein of 
interest – the Pollard laboratory have identified MYEF2 as a candidate interacting 
partner. MYEF2 contains multiple RNA binding domains and is expressed primarily in 
the brain and testis. Here I explored the function of MYEF2 within NSCs and GSCs.  
 
I confirm Myef2 is expressed within the brain, however was not specifically enriched 
in stem cell containing regions. CRISPR/Cas9 mediated knock-in of mCherry and HA 
to Myef2 was successfully carried out in mouse NSCs. We observed that MYEF2 is a 
nuclear protein which retains nuclear localisation and expression in both proliferative 
and quiescence NSCs, as well as differentiating progeny. During mitosis, unlike 
SOX2, MYEF2 is not retained on the mitotic chromatin indicating it is not a 
“bookmarking” factor. CRISPR/Cas9 mediated knock-out of Myef2 suggests that 
although it is not essential for the continued proliferation of GSCs, it has a role in 
regulating the exit from quiescence. Consistent with this, in Myef2 knock-out mouse 
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GSCs, the rate of tumour progression is slower, and mice have a significant survival 
advantage, suggesting there is an important role for Myef2 in driving tumour growth. 
 
In this thesis, I also describe the use of SMASh tag degron technology to precisely 
control the degradation of SOX2 in mouse NSCs. SMASh, a drug degradable self-
cleaving degron, was fused to the C-terminal of endogenous SOX2 in mouse NSCs. 








Glioblastoma is the most common primary brain cancer in adults. Prognosis is poor, 
with only 5% of patients surviving more than 5 years after diagnosis. A major 
contributor to this poor prognosis is the high level of disease recurrence, that occurs 
from a small number of tumour cells which evade current therapies. These tumour 
cells behave in an aberrant manner, capable of proliferating excessively and forming 
a tumour. These cells are controlled by many molecular pathways that are used in the 
developing brain. 
 
One factor involved in the proliferation of glioblastoma cells is a protein known as 
SOX2. SOX2 works in collaboration with many other proteins, many of which are still 
unknown. It is very difficult to generate therapies which directly target SOX2 using 
standard drug discovery methods. However, SOX2 interaction partners may be easier 
to block. To address this, we are identifying the binding partners of SOX2 within 
glioblastoma cells. Currently, one new factor that has been identified is MYEF2.  
 
During my PhD, I assessed the role MYEF2 plays in glioblastoma and if it is an 
essential partner of SOX2. In addition to studying MYEF2, I am expanding our 
experimental tools to study the functions of proteins in glioblastoma. One such tool is 
the SMASh tag system. Once established, this tool should allow us to understand 
better whether a particular protein is essential to tumour formation, and hence a good 
therapeutic target. These studies will further our understanding of glioblastoma and 
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Chapter 1 Introduction 
1.1 Overview  
Understanding the fundamental biology of cancer enables the generation of new 
rationally designed therapies. Glioblastoma multiforme (GBM) is the most common 
adult primary brain tumour and has a poor survival rate. The disease is driven by a 
glioma cancer stem cell (GSC) population, which has characteristics of neural stem 
cells (NSCs). One feature of GSCs, is high level expression of the core transcriptional 
network protein SOX2. Understanding the SOX2 interactome, and its function, may 
reveal new ways to target this protein for therapeutic gain. Major advancements in 
mammalian genome engineering, coupled with improved cell culture models, have 
made this more achievable than ever, allowing rapid large-scale investigations of 
proteins that have been previously understudied. 
 
This introduction will cover current literature on several key topics. Firstly, the biology 
of GBM, including discussion of the known common genetic mutations, the core 
transcriptional network and experimental models. Secondly, current mammalian 
editing methods with a focus on CRISPR/Cas9. The recent advancements in this field 
have led to an ever-expanding repertoire of sophisticated genetic manipulations that 
can be performed efficiently. Thirdly, the use of degrons to post-translationally control 
protein levels and thereby confirm key therapeutic targets. 
 
1.2 The biology of GBM 
1.2.1 Glioma, GBM and current treatment strategy 
The World Health Organisation (WHO) has classified over 130 types of brain cancer1 
which are graded on a scale of I-IV, with grade I-II corresponding to benign/low grade 
tumours and grade III-IV corresponding to high grade/malignant tumours. Gliomas 
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represent the most common brain tumours observed and are named due to the 
observed glial cell histology of the tumour. Gliomas are categorised into astrocytoma 
(from astrocytes), oligodendroglioma (from oligodendrocytes) or ependymoma (from 
ependymal cells). Grade IV astrocytoma, most frequently referred to as glioblastoma 
multiforme (GBM), is the most common high-grade primary brain tumour in adults, 
with tumours most often arising in the cerebral hemisphere, particularly the frontal and 
temporal lobes.  
 
Treatment for GBM comprises of surgery to remove the bulk tumour, radiotherapy 
and chemotherapy with temozolomide (TMZ). Whilst this intensive regime increases 
survival time2, almost all patient relapse and have a poor median survival rate of just 
~12-15 months. The blood-brain barrier, whilst partially disrupted in patients with 
GBM3, complicates drug delivery. More significantly, GBM is highly invasive making 
it impossible to remove all of the malignant cells during surgery4. The residual tumour 
is thought to contain a population of glioma cancer stem cells (GSCs), which trigger 
re-growth of the tumour. GSCs are relatively resistant to radiation therapy, through 
activation of the DNA damage checkpoint in response to radiation and efficient repair 
of radiation induced DNA damage5, and a subpopulation of these GSCs are in a 
quiescent state making them resistant to classical chemotherapy treatments such as 
temozolomide (TMZ)6–9.  
 
1.2.2 The cancer stem cell model and GSCs 
Adult stem cells, also known as somatic stem cells, have been identified in a range of 
tissues throughout the body10. Normal adult stem cells are tissue specific and exhibit 
the ability to self-renew and to differentiate into cell types of the tissue of origin. The 
cancer stem cell (CSC) hypothesis proposes that tumours are initiated and 
maintained by a subpopulation of tumour cells that share biological properties of 
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normal adult stem cells. This is based on observations that some human cancers 
have cells that express stem cell and progenitor cell markers, and have the ability to 
self-renew and differentiate, giving rise to tumours that phenotypically resemble their 
tissue of origin. While CSCs share properties of normal stem cells, the self-renewal 
of CSCs is deregulated, leading to upregulated proliferation. Proliferative signalling in 
cancer arises from many sources, with many of the genes that promote self-renewal 
being oncogenes, and often, signalling pathways involved in normal stem cell 
development (such as Wnt, Shh and Notch) are classically associated with cancer11. 
In addition to acquiring proliferative signalling, cancer must overcome the inherent 
tumour suppressive mechanisms of senescence (a state of permanent cell cycle 
arrest) and apoptosis (cell death), that provide tight control over uncontrolled 
proliferation. In response to DNA damage and oncogene activation, cells can undergo 
apoptosis or cellular senescence. These processes are regulated by Retinoblastoma 
protein (Rb) and p53 pathways, which are often inactivated in cancer. Additional, to 
avoid replicative senescence in response to telomere erosion, cells can either activate 
telomerase or extend telomeres through alternative lengthening of telomeres (ALT). 
These alterations, enable escape from control and hence tumour formation12,13. 
 
Some of the first evidence for the existence of CSC came from studies of carcinoma14 
and of human acute myeloid leukaemia (AML), where a subpopulation of cells initiated 
AML when transplanted into severe combined immune-deficient (SCID) mice15,16. 
Subsequently CSCs have been shown to exist within several solid tumours, including 
breast cancer17 and brain cancer18,19,20. Cells expressing the human neural stem cell 
marker CD13321 were found across a range of primary paediatric brain tumours, 
including astrocytomas. These CD133+ cells were found to have a capacity for 
proliferation, self-renewal and differentiation in vitro18,20. Subsequently, CD133 
expressing cells were shown to generate tumours in vivo19 with a xenograft phenotype 
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very similar to the original tumour, including recapitulation of the cellular heterogeneity 
observed in GBM. In the same year, independent studies showed that GBM 
generated cell lines could also generate tumours in vivo22. Subsequently, many other 
markers of GSCs have been identified including SSEA123,CD4424 and A2B525, though 
no single marker defines a universal GSC population26,27. 
 
GSCs express a range of immature neural stem and progenitor cell markers, including 
NESTIN and SOX2, which are considered as stemness markers. Within GBM GSCs 
can be found in range of different cellular states28 including proliferative, quiescent6–9 
and more differentiated states29. In the proliferative state cells express proliferation 
markers such as Ki67, and this state can be easily studied in vitro using proliferative 
NSC culture conditions. Quiescent label-retaining GSCs are associated with several 
features including: low RNA content; downregulation of cell-cycle progression genes 
such as CCNB1; upregulation of several tumour suppressor genes such as 
CDKN1A30, and expression of  CD931, a feature of quiescent neural stem cells32,33. 
The ability to mimic the quiescent state of GSCs in vitro is not yet well established, 
but evidence indicates that signalling from BMP4 and FGF2 can induce quiescence 
in NSCs (Maria Angeles Marques, Pollard lab), whilst BMP alone may induce 
quiescence in GSCs34. A range of more differentiated cell types can be observed 
within GBM, including astrocytic, neuronal and OPC/oligodendrocytic like cells, in line 
with the hierarchical CSC model. Exposure to differentiation signals both in vitro, such 
as serum or BMP4, and those in the in vivo environment, can induced the expression 
of differentiation markers within GSCs including, neuronal markers ß-tubulin/TUJ1 
and MAP2, astrocytic marker GFAP and oligodendroglial marker GalC35–37, with the 
relative proportions of each marker reflecting the original tumour phenotype. Some 
lines of evidence suggest that the differentiation of GSCs is not terminal, and the cells 
   
  5 
are plastic able to return to less differentiated states27,38,39, a cavate for the potential 
use of differentiation therapy in GBM. 
 
Experimental findings continue to support the function and existence of GSCs, 
including those of in vivo lineage tracing experiments which support the proliferative 
hierarchy40 expected from CSC models, though is it unclear whether the cells undergo 
a truly terminal differentiation. The study of CSCs can be complex. CSCs are not a 
single definitive cell type or state, and they can undergo epigenetic and genetic 
changes during tumour development and treatment. 
 
1.2.3 The genetics of GBM 
GBM tumours typically consist of morphically diverse cells, with heterogeneity being 
observed in both an intratumoral and intertumoral manner. This complexity occurs not 
only at the phenotypic level, but also on a genetic and epigenetic scale, with tumours 
similar in morphological and phenotypical appearance varying in treatment response, 
prognosis and can harbour a distinct spectrum of mutations (Figure 1.1). 
 
Understanding the biology of GBM at the phenotypic, genetic, epigenetic and 
transcriptional level may provide new opportunities for therapies. Consortiums, such 
as The Cancer Genome Atlas (TCGA)41, aid in providing a wealth of information on 
genetic disruptions – nucleotide substitutions, copy number aberrations, 
chromosomal rearrangements – as well as DNA methylation patterns and gene 
expression data from multiple GBM patients. Collating these large-scale analyses has 
expanded our knowledge of the catalogue of mutations associated with these 
tumours; however, we still have a poor understanding of how these operate 
functionally. 
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The first cancer reported by the TCGA was GBM in 200815, with an expanded study 
performed in 201316. In the GBM samples, mutations within the PI3K/RTK, p53 and 
RB1 pathways were consistently identified, with 90%, 86% and 79% of samples 
containing mutations within each pathway, respectively16. Mutations occur at several 
points throughout of these pathways: with mutations within MDM2, MDM4, CDKN2A 
and TP53 altering the p53 pathway; mutations within CDK4, CDK6, CCCND2, 
CDKN2A/B and RB1 altering the RB1 pathway, and mutations within PI3KCA, 
PIK3R1, PTEN, EGFR, PDGFRA and NF1 altering the PI3K/RTK pathway. The 
frequency of which a gene is mutated varies, with EGFR mutations found in 57.4% of 
GBM samples, whilst PDGFRA mutations are only seen in 13% of GBMs. These 
finding highlight, that highly heterogenous somatic mutations often converge onto 3 
core pathways. However, there is no single actionable driver mutation that 
encompasses all GBM patients. 
 
One aim of understanding the genetics, epigenetics and transcriptome of GBM is to 
identify biomarkers, to aid in the prediction of prognosis and response to treatment. 
For GBM, only a few functional biomarkers have been identified including IDH1/IDH2 
mutation status and the methylation prolife of MGMT. The isocitrate dehydrogenase 
enzyme IDH1 has been found to be mutated in 12% of GBMs. This mutation is 
primarily found in young patients and most patients with secondary GBMs– the 
progressive form of the disease that arises from lower grade tumours. Mutations in 
IDH1, and IDH2, are associated with an increase in overall survival42 and the WHO1 
now subdivides GBM into IDH mutant and IDH WT classes. O(6)-methylguanine DNA 
methyltransferase (MGMT), is a DNA repair enzyme. Promoter methylation mediated 
silencing of MGMT can lead lower level expression and correlates with better 
response to treatment with TMZ43. 
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1.2.4 Transcriptional subtypes of GBM 
Transcriptional profiling of GBM tumours has led to a proposed classification of 3 
transcriptional subtypes of GBM: Proneural (PN), Classical (CL) and Mesenchymal 
(MES)44,45, based on the mRNA profiles of bulk tumours. High levels of intra tumour 
heterogeneity are often observed, with multiple subtypes coexisting in the same 
tumour. Additionally, the bulk tumour subtype can change over time and after 
therapy28,45,46. Several genetic mutations correlate with the subtypes. The Pro-neural 
subtype correlates with PDGFRA amplification and TP53 mutations. The classical 
subtype with EGFR amplification, Chr10 loss, CDKN2A deletion and absence of TP53 
mutations. Finally, the mesenchymal subtype, which has elevated invasive potential, 
poor clinical prognosis, and significantly shortened time to recurrence following initial 
treatment when compared to other subtypes, is associated with NF1 loss and this 
NF1 deficiency may drive the higher levels of tumour associated 
macrophages/microglial infiltration associated with this subtype45.  
 
However, these are not robust classifications, and single cell analysis reveals more 
of a continuum of cell states and varied intratumoral genetic drivers. The subtypes are 
reminiscent of distinct neural cell types44. Recent single cell RNA analysis of IDH WT 
GBM29, in fact has found that malignant cells in GBM recapitulate different cellular 
states, including neural progenitor like (NPC), oligodendrocyte progenitor like (OPC), 
astrocyte like (AC) and mesenchymal like (MES) states.  The abundance of each state 
within a tumour, correlates with the transcriptional subtypes and the associated 
genetic mutations.  High abundance of the OPC and NPC like states are associated 
with the proneural subtype and PDGFRA/CDK4 mutations, respectively. High 
abundance of MES like state correlates with the mesenchymal subtype, NF1 loss and 
Chr5q deletions. However, this does not mirror any specific cell type and may instead 
be a transcriptionally corrupted state, with GSCs harbouring NF1 loss, PTEN loss and 
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EGFRVIII overexpression, expressing myeloid-specific master transcription factor 
interferon regulatory factor 8 (IRF8) via epigenetic immunoediting (Pollard lab, 
unpublished). Finally, high abundance of the astrocytic cellular state correlates with 
the classical subtype and EGFR amplification.  Cells can span over more than one 
cellular state and, through in vivo barcoding,  plasticity was identified, with a single 
cell capable of generating all four cellular states. These transcriptional signatures 
therefore are highly plastic29. 
 
1.2.5 The tumour microenvironment and epithelial-mesenchymal 
transitions  
In addition to cancer cells, glioblastoma tumours contain: non-cancerous cells 
including microglial/macrophages, dendritic cells, neutrophils, astrocytes, neurons, 
pericytes and endothelial cells; a brain distinct extracellular matrix, interstitial fluid, 
and the blood brain barrier, all of which constitute the tumour microenvironment 
(TME). The TME is dynamic, with therapeutic treatments such as temozolomide 
triggering TME remodelling, and plays a key role in tumour progression. One 
mechanism by which the TME contributes to tumour progression is through crosstalk 
between tumour cells and tumour associated microglial/macrophages (TAMs), with 
tumour cells secreting cytokines and chemoattractants whilst TAMs release pro-
survival and pro-tumorigenic factors which can contribute to epithelial-mesenchymal 
transitions (as discussed below)47,48. 
 
Epithelial-mesenchymal transitions, in which epithelial cells undergo multiple (often 
reversible) biological changes to switch to a mesenchymal cell type, occur during 
embryogenesis, organ development, wound healing and cancer, where the 
associated production of ECM components and altered migratory capacity, increase 
invasiveness and enable metastasis of cancer49,50. Whilst GBM rarely form 
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metastases outside of the CNS, they are highly infiltrative and can have diffuse 
growth51, with evidence indicating an EMT-like process occurs52 with the 
mesenchymal subtype having highest upregulation of EMT signature genes53. This 
EMT-like process, also referred to as GMT (glial-mesenchymal transition)54, is non-
classical with neural cells already assuming a mesenchymal phenotype and classical 
E-cadherin to N-cadherin switches are unlikely to correlate with EMTs, due to the 
absence of E-cadherin expression in GBM cultures55. Several core activators of EMT, 
including Twist, ZEB1/2, Snail and Slug, are upregulated during GMT and are 
triggered through WNT/ß-catenin, which is elevated in human GBM55–57, and TGF-ß, 
which is produced by tumour associated microglial/macrophages and in response to 
radiation therapy54,58. 
 
In summary, GBM is highly heterogenous at both intratumoral and intertumoral levels. 
Multiple factors contribute to the cell phenotype, including genetics, epigenetics, the 
microenvironment and dynamic changes in cell cycle or epithelial-mesenchymal 
transitions. 
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Figure 1.1 | GBM intratumoral heterogeneity 
Depiction of the intratumoral heterogeneity of GBM patient samples. The transcriptional 
subtypes, associated plastic cellular states (MES like = mesenchymal like, OPC like = 
oligodendrocyte progenitor like, NPC like = neural progenitor like and AC like= astrocyte 
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1.2.6 The cellular origins of GBM 
The cancer stem cell hypothesis does not propose to assume that the cell of origin of 
a CSC is a stem cell. However, this is an attractive theory, especially when combined 
with the multi-hit mutational theory. For this to occur in GBM, there must be a 
population of adult NSCs. Below is a brief summary of the development of NSCs with 
the mammalian brain, with evidence derived mainly from rodents59,60. 
 
Within development, neuroepithelial cells (NEPCs) are the earliest cells to arise which 
are considered as NSCs. NEPCs arise from the neural plate, following neural 
induction, and undergo symmetric division expanding their numbers. At the onset of 
neurogenesis, around E1161, NEPCs transition to a distinct progenitor/stem cell 
referred to as radial glial progenitors (RGs). RGs express a range of markers including 
Sox2, Blbp, Vcam1, Nestin and Glast. RGs undergo asymmetrical division from E11 
– E17, generating neurons directly or through generation of transient amplifying 
intermediated progenitor cells (IPCs)62. At later stages of development, RGs/IPCs 
switch from neurogenesis to gliogenesis, and finally at the end of embryonic 
development most RGs convert to astrocytes or ependymal cells. 
 
Some RGs, now referred to as adult NSCs, persist with at least two specific regions 
of the brain, the subgranular zone (SGZ) of the hippocampus and the subventricular 
zone (SVZ) of the forebrain.  NSCs of the SGZ express RG associated markers Sox2, 
Gfap and Nestin59, and their differentiation potential is largely restricted to the 
neuronal lineage63. In the SVZ, quiescent NSCs64 (also known as type B1 cells) 
express RG associated  markers including  Vcam1, Nestin, Gfap, Glast, and Sox259  
and have the potential to make neurons65, astrocytes, and to a lesser extent 
oligodendrocytes66. 
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The cell of origin of GBM is a controversial topic. Multiple views and lines of evidence 
exist, with some proposing that dedifferentiation leads to the generation of the cell of 
GBM origin. Cultured early postnatal astrocytes, which may not fully represent in vivo 
mature adult astrocytes, overexpressing EGFR coupled with the deletion of Ink4a/Arf 
are capable of developing tumours in immunodeficient mice67. A more commonly held 
view is that adult NSCs form the cell of origin. Induction of high grade gliomas in mice 
ablated of conditional alleles Nf1, Trp53 and Pten, either within the SVZ or within 
specific cell populations, support the proposition that neural progenitor cells or NSCs, 
including quiescent NSCs,  are the cell of origin68–72. In line with this the susceptibility 
to malignant transformation from the loss of Nf1, Trp53 and Pten decreases with 
increased lineage restriction73. Recent genetic analysis of human GBM samples and 
the corresponding tumour free SVZ, found the macroscopically normal tissue 
contained key GBM driver mutations, providing the most direct support to date that 
cells within the SVZ are the cell of origin74. 
 
1.2.7 Modelling GSCs and glioblastoma 
Until relatively recently, human glioma cell lines, such as U87MG, U251 and T98G, 
were commonly used. These lines, which are cultured in serum, do not reflect the 
NSC pathways that underlie GSCs and tumours formed upon xenotransplantation do 
not resemble GBM tumours75. On top of this U87MG, one of the most popular cell 
lines, does not match the original stock76. Because of this, the current gold standard 
for GBM models are now patient-derived lines and primary cultures. Culture 
conditions used to expand adult NSCs77, are applied to primary GBM specimens. 
These can be expanded continuously in culture and retain the genetic and 
transcriptional states of the parental tumour75. Patient derived lines can be grown as 
either adherent monolayers78, or using suspension culture conditions (spheres or 
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organoid conditions)79. Efforts are ongoing to derive repositories of well annotated 
high quality patient derived glioma cell lines, as well as isogenic pairs with driver 
mutations reverted to wild-type (http://www.gcgr.org.uk). 
 
Whilst patient-derived lines are highly valuable, they can be slow to expand and, like 
the patient disease, genetically heterogeneous making deconvolution of observations 
more challenging. GCSs recapitulate many signatures of NSCs, making NSCs the 
obvious cell for in vitro modelling, in vivo modelling, and dissecting the downstream 
effectors of the common driver mutations. 
 
Genetically engineered mouse models are a major experimental model and a tool for 
preclinical models and for studying the aetiology of glioma. Often, mice are 
engineered to mimic key driver mutations including loss of function of tumour 
suppressor gene such as Cdnk2a (Ink4A/Arf), Nf1, Trp53, Pten and Rb1, combined 
with expression of key oncogenes such as Ras, although this is not typically mutated 
in GBM. In this thesis, the mouse tumour initiating cell line referred to as IENS was 
used: this line was derived from the retroviral introduction of constitutively active 
mutant EGFRvIII to NSCs derived from, cdkn2a encoding, p16Ink4A/Arf deficient 
mice80. Genetically engineered mouse models have a key function but are expensive 
and time consuming to breed and maintain, particularly when compound mutations 
are required. A complementary approach is to engineer the glioma driver mutations 
into normal NSCs. 
 
CRISPR/Cas9 mediated gene editing allows for the rapid and precise editing of both 
human and mouse NSCs, both in vitro and in vivo81. Combined with transgenic 
methods, such as piggyBac integration, multiple modifications can therefore be 
engineered simultaneously, rapidly enabling modelling of different genetic subtypes. 
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One novel example used within this thesis is the mouse GSC model referred to as 
NPE (Pollard lab, in preparation). Using sgRNAs against the corresponding genes, 
Nf1 and Pten were ablated, while transgenic constitutively human active EGFR 
(EGFRvIII) is overexpressed using transposase (piggyBac) mediated integration. This 
model most closely recapitulates the mesenchymal subtype of GSCs and models 
simultaneous activation of PI3K and MAPK signalling pathways, without interference 
with p53, thereby limiting genome instability. Models generated through this manner 
can be produced quickly and enable comparisons of isogenic pairs of mutant and 
parental cells (Figure 1.2). 
 
1.3 The core transcriptional network of GSCs 
GSCs, like NSCs, have a core transcriptional network that is responsible for their cell 
type identity. The induction of four core transcription factors (TFs), POUF3F2, SOX2, 
SALL2 and OLIG2, has been shown to be sufficient to reprogram differentiated glioma 
cells into GSCs capable of in vivo tumour formation82. These factors are all aberrantly 
upregulated in GBM83, across a range of genetic subtypes. 
 
SOX2 and OLIG2, in combination with ZEB1 can also transform tumour suppressor 
deficient astrocytes into glioma initiating cells, even in the absence of PI3K/RTK 
overexpression84. In line with the ability of SOX2 to reprogram mature cell types85, 
overexpression of SOX2 cooperates with FOXG1 to dedifferentiate astrocytes, 
mediating acquisition of NSC like characteristics and re-entry to a proliferative state86. 
In summary, GSCs express a wide number of core neurodevelopmental, ‘master 
regulators’ and these seem to be critical for their sustained self-renewal. SOX2 is a 
key component of this gene regulatory network.  
 
 
   
  15 
 
Figure 1.2 | Review of commonly used GBM models 
Figure depicting common GBM models. GBM patient tumour samples can be used to 
derive patient lines, which retain the heterogeneity reflected within the original patient 
sample. Breeding mouse models can be used for both in vivo studies and may also be 
used to derive in vitro models. In vitro models of GBM may also be obtained through 
CRISPR/Cas9 mediated engineering of normal NSCs. This figure was generated using 
Biorender. 
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1.3.1 Sry-related HMG box transcription factor, SOX2 
In mice and humans, ~20 Sox (SRY-related HMG-box) family members have been 
identified, based on the presence of a highly conserved high-mobility group (HMG) 
domain which mediates DNA binding87. Sox members are divided, based on HMG 
sequence identity, into the groups A-H, with factors from different groups having 
distinct biological functions in a wide range of stem cells and tissues88. The SoxE 
family, composed of Sox8, Sox9 and Sox10, is capable of forming homo- and hetero-
dimers with members of its family. Sox8, Sox9 and Sox10 are all involved in neural 
crest specification89, with Sox10 playing a role in the maintenance of migratory neural 
crest stem cells within mice90. Sox9 is also involved in: chondrogenesis91; sex 
determination, with evidence also indicating a role for Sox8 in Sertoli cell function92–
95; pancreatic progenitor maintenance96, and neural stem cell specification and 
maintenance97–99. This versatility of SOX9 is achieved through a combination of post-
translational modifications and varying binding partners. For example, 
phosphorylation of SOX9, by protein kinase A, can enhance DNA binding affinity and 
cause SOX9 translocation into the nucleus in testis cells, while in neural crest cells 
phosphorylation is required for SOX9-SNAIL interaction. The varying binding partners 
of SOX9 are relatively well studied with many examples existing, including SOX9 
interacting with NFIA during glial initiation in the CNS, whilst during sex determination 
SOX9 can either homodimerize to regulate prostaglandin D synthase or SOX9 can 
interact with SF1 to upregulate anti-Mullerian hormone100. The SOXB1 family is 
composed of Sox1, Sox2 and Sox3. Sox1 has been shown to play a role in lens 
development101, and all of the SOXB1 family are involved in the specification and 
maintenance of neural progenitor cells102. Sox3 has also been shown to be involved 
in the progression spermatogenesis103. Of particular interest to this thesis is the 
SOXB1 family member Sox2 (Fig 1.3) which has key roles throughout development, 
in adult tissue homeostasis and in disease progression104. 
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Sox2 is initially expressed in the inner cell mass (ICM) and trophectoderm of 
blastocysts, with the zygotic deletion of Sox2 resulting in a failure to form the 
pluripotent epiblast and early embryonic lethality105. Supporting the key role of Sox2 
in the establishment and maintenance of pluripotency, embryonic stem cells lacking 
SOX2 inappropriately differentiate into trophectoderm-like cells106, whilst the forced 
expression of Sox2, Oct4, Klf4 and c-Myc enables conversion of fibroblasts to induced 
pluripotent stem cells85,107.  
 
After exit from pluripotency, Sox2 plays critical roles in foetal development of several 
endodermal tissues, ectodermal tissues and foetal germ cells104. In development, 
Sox2 regulates early neural specification108 and continues to play major roles, with 
other SOXB1 members,  in the developing CNS and PNS, controlling the proliferation 
and differentiation of foetal progenitor cells109,110. Generally, overexpression of 
SOXB1 members (Sox1, Sox2 and Sox3) promotes NPC proliferation, whilst the 
depletion of SOX2 causes exit from the cell cycle and premature differentiation102,111.  
 
In the adult, SOX2 has been found to be expressed in within cells of multiple tissues, 
including the stomach, cervix, anus, testes, lens and multiple glands, with several of 
the tissues that require Sox2 in development containing Sox2 expressing adult stem 
cells/progenitors. Lineage tracing experiments have shown these SOX2+ adult stem 
cells originate from foetal SOX2+ tissue progenitors and are required for tissue 
homeostasis and regeneration104,112. Sox2 also marks adult NSCs63,113 found within 
neurogenic regions of the adult brain, where it is required for the maintenance of 
NSCs properties and functions114–116. Consistent with the core function of Sox2 in 
NSCs/NPCs, overexpression of Sox2 alone is sufficient to generate induced NSCs 
(iNSCs) from mouse embryonic fibroblasts117. 
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SOX2 is genetically amplified in  ~4% GBM16,  and SOX2 is often highly expressed in 
GBM118, with upregulated expression observed in patient derived xenografts 
irrespective of the oncogenic driver84. Reflecting Sox2’s function in normal NSCs, 
Sox2 is key for GSCs migration/invasion119, in vivo tumour formation and 
proliferation84,119–121, with a recently published genome-wide CRISPR viability screen 
identifying SOX family members as top hits122. 
 
Despite its potential importance as a therapeutic target, the lack of enzymatic sites 
makes SOX2 difficult to ‘drug’ therapeutically using small molecules. SOX2’s activity 
is controlled in multiple ways; through control of expression including post-
transcriptionally by miRNAs123, co-partner expression and post-translational 
modifications (PTMs), offering potential alternative SOX2 targeting routes. Several 
PTMs, including phosphorylation, methylation, acetylation, SUMOylation, 
ubiquitination, PARPylation and O-GlcNAcylation, have been identified to occur on 
SOX2. The function of many of these PTMs is still being eluted, but evidence shows 
they can mediate effects on protein turnover, nucleo-cytoplasmic transport, DNA-
binding and protein interactions (Figure 1.3)124,125. As SOX proteins general exhibit 
gene regulatory functions through complexes, with target genes often having partner 
protein binding sites adjacent to functional SOX-binding sites, the protein interactors 
of SOX2 effect activity of SOX2 and contribute to the activation of alternative 
transcriptional targets126,127. For example, the UTF1 enhancer128 and the Fgf4 
enhancer are activated by SOX2-POU5F1/OCT4 heterodimers, but not SOX2 alone, 
in ESCs129, while the chicken δ -crystallin gene minimal enhancer, DC5, is activated 
by SOX2 and PAX6 during lens development130. Understanding the transcriptional 
targets and SOX2 protein interaction partners within GBM may provide novel 
alternative strategies to disrupt SOX2’s function. Recent integration of genetic and 
proteomic approaches led to the identification of CHD7 as a functional interactor of 
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SOX2 in mouse NSCs, highlighting the capability of this approach131. Through 
proteomic approaches the Pollard laboratory has recently identified MYEF2 (Myelin 
expression factor 2) to be an interactor of SOX2 and understanding the function of 
MYEF2 in GBM will form the basis of a subsection of this thesis. 
 
MYEF2 is a ~65kDa paralogue of hnRNPM with known ssDNA132 and RNA 
binding133,134 properties, most likely conferred through its three RRM domains. A N-
terminal truncated version of MYEF2 was identified to be capable of binding to a single 
stranded probe generated from the myelin basic protein (mbp) proximal promoter 
region MB1, repressing expression from the myelin basic protein (MBP) promoter in 
non-glial cells but not in glial cells132. No validation of the full-length protein has been 
performed.  MYEF2 has also been identified to form a complex with RUNX1 in mouse 
erythroleukemia cells, contributing to the repression of several RUNX1 targets and 
morpholino knockdown of myef2 in zebrafish leads to a reduction in the numbers of 
HSCs, highlighting a role for myef2 in the regulation of haematopoiesis135. Intriguingly, 
a link between sox2 and myef2 has previously been identified within mouse squamous 
skin tumours. Whilst SOX2 is absent from the normal epidermis, SOX2 is the most 
upregulated transcription factor in the cancer stem cells (CSCs) of mouse squamous 
skin tumours. Within the SOX2 expressing CSC population myef2 levels increased 
while knockdown of SOX2 in pre-existing tumour cells led to a reduction of myef2, 
with SOX2 ChIP identifying myef2 as a direct target of SOX2 in squamous skin CSCs. 
It should be noted that SOX2 ChIP in glioblastoma did not identify myef2 as a direct 
SOX2 target and KD of SOX2 did not lead to a reduction in myef2 in one human 
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Figure 1.3 | SOX2 and post-translational modifications 
SOX2 (SRY-related-HMG-box 2) contains an HMG domain and a C-terminal 
transactivation domain, as depicted. SOX2 can undergo a range of post-translational 
modifications including sumoylation (red), phosphorylation (green) and O-GlcNAc 
glycosylation137 (grey, dotted). Other modifications such as acetylation and methylation 
can also occur. O-GlcNAcylation of SOX2 on Ser248,Thr258 and Ser259 (mouse)  has 
been observed to occur in mESCs137 and the rat forebrain138, and has been shown to alter 
SOX2’s protein interactions and genomic occupancy139.AKT-dependant phosphorylation 
at Thr118 (mouse)/THR116 (human) is associated with increased stability140, while 
phosphorylation at residues SER249-251(human)141 in hESCs, leads to the sumoylation 
of residue Lys245 (human), which is associated with inhibition of transcriptional 
activation142. Acetylation of residue Lys75 (mouse) within the nuclear export sequence of 
SOX2 effecting subcellular localisation and protein decay143. Methylation of Arg113 
(mouse), has been proposed to effect SOX2 homo-dimerisation144 and methylation of 
Lys119 (mouse) can effect SOX2 ubiquitination and hence decay of SOX2145,146. Figure 
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1.4 Genome editing 
Genome editing is the site-specific deletion, insertion or replacement of DNA within 
an organism. The first examples of targeted genomic editing came from targeted gene 
disruption studies in yeast147 and subsequently mammalian cells148,149. In these 
studies, the directed integration of the exogenously provided DNA was dependant on 
homologous recombination (HR). Despite this major advance, this approach had 
several limitations including, low efficiency of targeted integration150 and random 
integration of the exogenous DNA, which could occur at a frequency higher than the 
targeted events151.  Introduction of a double stranded break (DSB) within the DNA of 
the target site, promotes HR-directed DNA repair (HDR), improving the efficiency of 
targeted integration by orders of magnitude152,153. DSBs can also be repaired through 
the alterative pathway of non-homologous end joining (NHEJ). NHEJ is an error prone 
repair pathway which can result in the insertion and deletions of nucleotides at the 
break site (Figure 1.4). 
 
The first enzymes used to induce DSBs were the rare cutting endonucleases, such 
as the 18bp cutter I	-SceI153. These meganucleases recognise long stretched of DNA 
(14-40bp), hence the probability of a recognition site occurring at the desired genomic 
location is low. Overcoming this, fusion of DNA recognising zinc finger proteins and 
transcription activator-like effector (TALE) proteins, to the DNA cleavage domain of 
Fok	 I endonuclease, led to the generation of zinc finger nucleases (ZFNs)154 and 
TALENs155, respectively. As Fok I functions as a homodimer two separate ZFN or 
TALENs are required mediate a DSB. Each ZFN recognises a 3-bp DNA sequence156, 
while each TALEN recognises a single base pair157,158. Combinations of zinc fingers 
and TALENs can be combinatorially assembled to target unique genomic sequences. 
These ‘designer nucleases’ successfully increase genome editing efficiency159–162. 
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However, targeting of new genomic locations requires re-design and synthesis of 
extensive and repetitive structures. This protein engineering is burdensome and 
difficult for non-experts.  
 
1.4.1 Discovery of CRISPR/Cas9 
Due to its flexibility and simplicity, the development of CRISPR/Cas editing technology 
has changed the field of genome editing. CRISPR (Clustered Regularly Interspaced 
Short Palindromic Repeats)163 and their CRISPR associated (Cas) genes164 form a 
prokaryotic adaptive immune mechanism165. CRISPR repeat clusters are separated 
by non-repeating spacer DNA sequences. These spacers are derived from DNA of 
the invading pathogen and dictate the targeting specificity of Cas enzymes, which 
mediate the introduction of DSBs into the pathogen’s DNA upon reinfection.  
 
Several types of CRISPR/Cas systems have been reported across different bacteria 
and archaea166. All systems require a short CRISPR RNA (crRNA), transcribed from 
the spacer sequence167, and a transactivating crRNA (tracrRNA)168 to form an active 
Cas protein-RNA complex. A single chimeric RNA, termed single guide RNA (sgRNA), 
formed by the fusion of crRNA and tracrRNA may also be used169. The crRNA acts 
as the guiding sequence, hybridising to the target DNA sequence, which is positioned 
next to a protospacer adjacent motif (PAM)170, a critical component of the system that 
mediates the distinction of self and non-self DNA171.  
 
Currently, the most commonly used CRISPR/Cas system for genome editing is 
CRISPR/Cas9, a type II CRISPR system from Streptococcus pyogenes. This system 
has a single effector protein (SpCas9), a 20nt long crRNA and simple NGG PAM 
requirement, with the cut site generated ~3bp 5’ of the PAM172. Following proof of 
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principle in vitro experiments169, the CRISPR/Cas9 system was successfully used for 
mammalian genomic editing173–175 and continues to be extensively used. 
 
Compared to previously used ZFNs and TALENs, the CRISPR/Cas9 system is 
simple, cost effective and efficient. By altering the sequence of the crRNA, Cas9 can 
be programmed to new target sites with the genome, without the burdensome design 
and synthesis associated with ZFNs and TALENs. The simple NGG PAM 
requirements of the CRISPR/Cas9 allow for appropriate targets to be identified at a 
high density throughout the genome176, although this is obviously not as flexible as 
TALENs which in theory should be capable of targeting any genomic region. In 
attempts to expand the application of CRISPR researches are still exploring other 
CRISPR systems, identifying systems which varying in their PAM requirements, 
substrate preferences and effector protein size177. An overview of the versatile uses 
of CRISPR/Cas technology are discussed below (Figure 1.5). 
 
1.4.2 CRISPR/Cas9 for gene knockouts 
The co-delivery of Cas9 with an sgRNA targeting an exonic region within the gene of 
interest, is the simplest method to knockout the protein of interest. Indels introduced 
by the NHEJ mediated repair of the DSB can disrupt the reading frame, leading to 
generation of a non-functional protein product174. Alternatively, two guide RNAs can 
be used to target two sites in a gene, leading to a deletion of the intervening sequence, 
which can be up to a megabase in size178. The high efficiency of this method, coupled 
with the easy large scale generation of multiple sgRNAs, have subsequently allowed 
for CRISPR/Cas9 mediated high-throughput loss of function screens179–181. 
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Figure 1.4 | Site specific DSB facilitates precise genome editing 
Programmable nucleases, such as Cas9, are recruited to specific regions of the genome 
where they mediate the generation of double strand breaks (DSBs). These DSBs can be 
repaired through two pathways: NHEJ (non-homologous end joining) or HDR (homology 
directed repair). In NHEJ, the ends of the DBS are process and re-joined. This can result 
in random indel mutations at the junction site. In the presence of a DNA sequence with 
homology to the damage region, HDR can seal the DSB in an error free manner and can 
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Figure 1.5 | The CRISPR/Cas “tool kit” 
Depiction of some of the many uses of CRISPR/Cas for genome editing and beyond. 
CRISPR/Cas can be used for the generation of genetic knockouts through multiple 
methods including NHEJ mediated indel formation, exon drop out, exon replacement or 
the insertion of recombination sites. CRISPR/Cas can also be used to insert fluorescent 
tags or epitope tags to endogenous genes. Besides genome editing, the fusion of Cas9 
mutants to a range of proteins can mediate a multitude of outcomes including base editing, 
transcriptional control and epigenetic modification.  
Gene knockouts
Reporter alleles Nucleotide substition and base editing























Transcriptional repression DNA demethylation
DNA methylation
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Alternatively, the Cas9/sgRNA can be delivered in the presence of exogenous DNA 
with homology to the targeted region. Upon DSB induction, HR-directed repair may 
occur, integrating the exogenously supplied DNA. This can allow for the replacement 
of a specific region, generating non-functional protein and a method to select for 
targeted cells. CRISPR/Cas9 may also be used to integrate flanking loxP or FRT sites, 
allowing for the generation of Cre-LoxP or Flp-FRP conditional knockout alleles182–184 
 
1.4.3 CRISPR/Cas9 for gene knock-ins of tags and reporters 
HR-directed repair, following CRISPR/Cas9 generated DSBs, can be used to 
introduce a wide variety of sequences to protein-encoding genes. Proteins of interest 
can be engineered at the N-terminal, C-terminal or at internal regions such as within 
flexible loops. CRISPR/Cas9 can be utilised to insert large DNA sequences encoding 
fluorescent markers, such as GFP or mCherry81, or for the insertion of small epitope 
tags, such as HA, FLAG or V5185. The generated in-frame fusion proteins can be used 
for biochemical studies and as an alternative for low quality or unavailable antibodies. 
Fluorophores may also be used for real-time observations, such as live-cell imaging 
or live isolation of specific cell populations. 
 
Other uses of CRISPR/Cas9 mediated knock-ins include HDR mediated insertion of 
point mutations within the coding sequence. These can be disease specific mutations, 
expanding the availability of disease models in vitro and in vivo186. More recently, 
there has been interest in base editing. A ‘nickase’ Cas9 (nCas9) can be fused to 
APOBEC1 deaminase enzyme and Uracyl Glycosylase inhibitor (UGI), mediating the 
conversion of cytosine (C) to Thymine (T)187. These base editing tools can be used to 
introduce single base pair mutations, including generating the introduction of stop 
codons in method known as CRISPR-STOP188. 
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1.4.4 Transcriptional and epigenome editing with CRISPR/Cas9  
Catalytically inactive Cas9 (dCas9), cannot cleave DNA but still binds to its target 
sequence189. In fact, the strong binding of dCas9 to DNA can interfere with the binding 
of DNA binding proteins such as RNA polymerase lI. This can block transcription and 
lead to a knockdown in protein expression in a method now referred to as CRISPRi189. 
The fusion of a repressor complex, such as Kruppel-associated Box (KRAB) 
enhances this effect190. In the reverse manner, fusion of dCas9 or nCas9 with strong 
transcriptional activators, such as VP64, can induce transcription from the target 
gene191–193. 
 
dCas9 fusion proteins may also be exploited to introduce epigenetic modifications to 
specific regions of the genome. dCas9 fused to the catalytic domain of DNA 
methyltransferase 3A (DNMT3A) is capable of depositing DNA methylation at the 
targeted locus. This can recruit additional repressive components, such as DNMT3L, 
causing gene suppression194,195. By contrast, dCas9 can be fused to the catalytic 
domain of methyl cytosine dioxygenase TET1, resulting in the demethylation of the 
targeted sequence and reversal of gene silencing196. 
 
1.4.5 Targeting RNA 
It has recently been shown that the CRISPR/Cas9 system can be used to bind or 
cleave specific RNAs. Through the addition of a PAM presenting oligonucleotide 
(PAMmer), Cas9 can be directed to ssDNA. If the PAMmer sequence is designed for 
RNA sequences that lack PAMs at the corresponding genomic site, Cas9 will 
specifically target RNA. This RNA-Cas9 targeting system is referred to as RCas9197. 
RCas9 can be used in manners similar to those discussed above including cleavage 
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of RNA and RNA visualisation198 and is being increasingly used to explore the RNA 
epigenome. 
 
1.4.6 Strategies to deliver CRISPR/Cas9 to cells 
As only one CRISPR/Cas9 complex is required to generate a DSB, compare to the 
two required for ZFNs and TALENs, CRISPR/Cas is considered to be more 
susceptible to off-target effects. This has led to the generation of several design tools 
to predict such off-target sites (such as GUIDE-seq, BLESS, HTGTS, and Digenome-
seq). However, one of the easiest methods to reduce off-targets and increase the 
efficiency of targeting is to alter the exact components delivered.  For example: The 
catalytic domain of SpCas9 can be mutated to produce a ‘nicking’ enzyme, 
nCas9174,199,200. Unlike wild-type spCas9, nCas9 requires the use of 2 guide RNAs to 
introduce nicks on both strands at a proximal distance. This significantly reduces off 
target effects. 
 
Most commonly, Cas9 is delivered into cells in either an expression plasmid-based 
manner or as a purified protein pre-complexed with crRNA/tracrRNA; this is referred 
to as an RNP (ribonucleoprotein). Delivery of Cas9 as an RNP results in more 
transient Cas9 activity, compared to the more prolonged expression observed when 
delivered as a plasmid. This more transient nature of the RNP leads to fewer off-target 
effects201,202, though may not be suitable if long term expression of Cas9 is required. 
Delivery of RNP is also associated with lower toxicity in primary cells and the 
efficiency of targeting can be very high202,185,203. 
 
To mediate HR-directed repair, a donor template with a region of homology to the 
target is required. Typically, the repair template is provided as a plasmid, a dsDNA 
block or as ssODNs (single stranded oligonucleotides). However for primary cells 
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which are difficult to transfect the donor template may be delivered in the form of viral 
vectors, such as adeno-associated virus204. Synthetic ssODN are easy to obtain, 
though currently limited in size, and are not associated with plasmid related toxicities. 
Recently, it has been shown to be possible to generate long ssODNs using nickase 
enzymes expanding their potential use184. 
 
In summary, CRISPR/Cas9 has transformed the genetic analysis of human cancer. 
The possibilities to engineer specific mutations in patient derived cells or primary stem 
cells, and the ability to generate new tools for use in cell biology, imaging, biochemical 
and genomics methods, is opening up a wealth of new discoveries.  
 
1.5 Degron mediated post-translational control of protein levels 
Loss of function experiments are extremely useful in aiding the characterisation of the 
biological functions of a protein. To achieve these loss of function studies, genes and 
the corresponding proteins they encode can be disrupted at either the DNA, RNA or 
protein level. Traditional DNA modifying methods facilitate the generation of gene 
knockouts mediating the constitutive loss of encoded protein205. The generation of 
gene knockouts has been greatly eased by the emergence of genome editing 
technologies such as TALEN, Zn finger nucleases and in particular CRISPR/Cas9.  
Gene knockout experiments can be problematic when studying the function of 
proteins which are essential to cellular homeostasis, proliferation or during specific 
developmental periods. To overcome this, conditional genetic knockouts can be 
generated through the use of recombinases such as Cre. However, a relatively long 
time is required to see protein depletion, and once induced these genetic changes 
are permanent. To overcome some of these caveats, protein expression can be 
controlled reversibly at the DNA, RNA and protein level.  
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CRISPRi189, as discussed previously, is one method of controlling expression 
conditionally and reversibly at the pre-transcriptional level. Catalytically dead dCas9 
co-expressed with sgRNA, can prevent the initiation of transcription from the targeted 
locus. This system can be inducible through controlled expression of dCas9 or 
sgRNA, although the method is limited by the requirement to have a PAM at the right 
site.  
 
At the RNA level siRNA/shRNA can be used. However these methods are associated 
with off-target effects and the efficiency of siRNAs mediated knockdown can be highly 
variable206. Delivery and stability of siRNA is also an issue for whole animal studies207. 
 
All the methods described above involve targeting DNA and RNA. This meditates 
control at the pre-translational level; hence a long time is required before a loss of 
protein is observed and does not realistically model the goal of a successful small 
molecule or biological therapeutic, which would knockdown or ablate protein 
activity/function acutely. For example, siRNA requires 2-3 days to issue an effect, and 
the exact rate relies on the half-life of the protein studied. This can be an issue if rapid 
degradation is required, for example if studying cell cycle proteins. This issue can be 
overcome by mediating control at the post-translation level. To achieve this, 
investigators are exploiting sequences known as degrons, which can be tethered to 
the protein of interest (POI)208. 
 
1.5.1 What is a degron? 
Within eukaryotic cells the levels of proteins can be controlled through degradation by 
the 26S proteasome or the lysosome. This degradation is highly selective, and control 
is mediated through degradation signals knowns as degrons. Degrons can be 
generally classified into two categories: acquired or inherent. Acquired degrons are 
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generally transient, and mediated through the addition of post-translation 
modifications, most frequently phosphorylation, to a protein. Acquired degrons are 
most commonly associated with controlling the levels of regulatory proteins, for 
example the rapid temporal degradation of cyclins/proteins through the cell cycle209.  
 
Inherent degrons are an internal feature of the protein, and often associated with the 
protein quality control system which exists to degrade misfolded or damaged 
proteins210. Internal degrons can be composed of hydrophobic stretches of amino 
acids which are normally buried within the protein but are exposed when proteins fail 
to correctly fold or assemble into relevant protein complexes. Alternatively, they can 
be specific amino acid sequences such as those observed in the N-degron and C-
degron pathways211. The first degron identified was an N-degron. The N-degron is 
composed of destabilising N-terminal residues, and in the case of eukaryotes an 
internal lysine substrate, which are recognised by E3 ubiquitin ligases and mediate 
26S proteasomal degradation effecting the proteins half-life212,213. With destabilisation 
initially only thought to occur through N-terminal residues, destabilising C-terminal 
residues have been subsequently identified and are referred to as C-degrons214. 
 
A key feature of degrons is that they are transferable, with the engineering of a degron 
to a protein of interest (POI) conferring a shorter half-life215. The combination of the 
transferable nature of degrons and the identification of N-degrons, lead to generation 
of the first conditional degron216. This degron could be engineered to a POI allowing 
for post-translation protein control. Subsequently, more conditional degrons have 
been generated. Combined with CRISPR/Cas9 mediated ease of genetic 
engineering, it is now possible to achieve the rapid, reversible controlled protein 
degradation using conditional degrons controlled by varying features including light, 
temperature, and small molecules as discussed below (Figure 1.6).	
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1.5.2 Temperature controlled degron 
The first conditional degron was generated by the Varshavsky laboratory216. Using 
their knowledge of N-degrons the temperature sensitive dihydrofolate reductase, Arg-
DHFRts, as fused to Ura3. Arg-DHFRts is a variant of DHFR in which the wild type N-
terminal Valine is replaced by the destabilising amino acid Arginine (Arg). At 23oC 
degree, in spite of a destabilising N residue, Arg-DHFRts is long lived. Increasing the 
temperature to 37oC causes unfolding of Arg-DHFRts, with the increased exposure of 
destabilising Arg and/or increased mobility of its internal lysine residue, resulting in 
rapid ubiquitination and 26S proteasome mediated degradation of the Arg-DHFRts-
Ura3 fusion protein. It should be noted that this system is only suitable for N-terminal 
tagging and its use has been limited to budding yeast and fission yeast due to the 
temperature sensitivity of plants (too high) and mammalian cells (too low). 
 
1.5.3 Light controlled degrons  
Phototrophins, a group of light activated kinases, allow plants to respond to external 
light cues. The light oxygen voltage 2 (LOV2) domain of phototropins contain a flavin 
mononucleotide binding core domain and a C-terminal Ja helix. Upon irradiation with 
blue light, a cysteine of core domain forms a covalent adduct with the excited flavin 
mononucleotides, inducing dissociation and unfolding of the Ja helix217. Fusion of the 
LOV2 domain with cODC, the C-terminal ubiquitin independent degron of ornitihine 
decarboxylase, led to the generation of a photosensitive degron (PSD). The PSD is 
stable in the dark, but upon irradiation with blue light, conformational changes within 
the LOV2 domain unmask the cODC degron, hence causing degradation in response 
to blue light218. Another light sensitive degron, B-LID, which consists of LOV2 - RRRG 
degron fusion protein has also been shown to be activated by blue light219. These 
photosensitive degrons offer short POI depletion times (t1/2=30 min), and both 
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temporal and, unlike other degrons, spatial control of POI degradation as exposure to 
light can be restricted.	 It should be noted that the use of these degrons requires 
specialised illumination devices. 
 
1.5.4 Small ligand/ molecule controlled degrons 
This is the largest group of conditional degrons. Many have been identified which can 
be used on the N- or C-terminal and avoid the use of heat shock or expensive 
illuminators. This type of degron is often relatively easy and cheap for in vitro studies, 
hence is extensively used. Below we discuss three commonly used degrons. 
 
Perhaps, one of the best known conditional degrons is the auxin inducible degron 
(AID), which is based on the plant auxin dependant degradation pathway. The auxin 
family hormones, such as IAA (naturally occurring auxin) and NAA (synthetic), bind to 
the F-box transport inhibitor response 1 (TIR1) protein, promoting the interaction of 
the E3 ubiquitin ligase SCF-TIR1(a form of SCF complex containing TIR1) and the 
degron domain of target auxin/IAA transcription repressor proteins. SCF-TIR1 recruits 
an E2 ubiquitin conjugating enzyme which leads to the ubiquitylation and subsequent 
proteasome mediated degradation of AUX/IAA protein. The SCF complex is highly 
conserved among eukaryotes, allowing plant TIR1 to form complex with non-plant 
SCF. Orthologues of TIR1 and AUX/IAA on the other hand, are only found in plant 
species. Fusion of the AID degron, derived from the auxin dependant degron 
sequence of IAA17, to the POI leads to rapid auxin-dependant degradation 
(t1/2=30min) in all non-plant eukaryotes which have been engineered to express high 
levels of TIR1220. 
 
 
   
  34 
 
Figure 1.6 | Commonly used conditional degrons 
This figure depicts several of the most commonly used conditional degrons, which when 
fused to the protein of interest (POI) allow for post-translational control. These degrons 
can be controlled through varying factors including: Temperature (ts-degrons); blue light, 
as is the case for degrons PSD and B-LID, and small molecules which control many 





























































Proteosome mediated degradation of POI 
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The HaloTag, derived from bacterial dehalogenase, is a highly versatile tag forms 
specific covalent bonds with compounds that contain alkyl chloride, allowing its use 
for a range of methods including cell imaging and protein purification221. Whilst the 
Halo tag itself is not a degron the covalent bonding between the HaloTag and specific 
binding partners can generate a conditional degron. One such example is HyT13, a 
small hydrophobic molecule which covalently binds to the HaloTag, and mimics a 
denatured or misfolded protein mediating the decay of HaloTag and fused POI 
through the protein quality control system222. Another example is through the use of a 
small molecule ligand of VHL, which when bound to the HaloTag mediates the 
recruitment of E3 ligase, VHL, and subsequent degradation by the proteasome. This 
degron is known as a HaloPROTAC223. It should be noted that one disadvantage of 
these degrons is that the rate of degradation is relatively slow compared to other 
degrons such as AID. 
 
Use of these degrons requires the fusion of a large tag which is retained on the POI. 
This may affect the normal function of the POI. Secondly, the use of AID requires dual 
engineering, and due to the relatively high amounts of auxin required to induce 
degradation, the AID system is problematic when it comes to multicellular organisms. 
The small molecule-assisted shut off SMASh tag224 is a self-cleaving degron, 
composed of a hepatitis C virus (HCV) NS3 protease, a HCV NS3 cleavage sequence 
and HCV NS4A degron. The exact mechanism of the NS4A degron is unknown but it 
has been proposed that that the hydrophobic NS4A N-terminal, which in the native 
protein normally inserts into the ER, is incapable of ER insertion in the modified 
SMASh peptide, hence is free and acts as a degron. When fused to the POI the 
SMASh tag normally self-cleaves, and only the SMASh tag is degraded. Addition of 
HCV NS3 protease inhibitors, such as asunaprevir (ASV), prevent the self-cleavage 
of the SMASh tag, mediating degradation of both the SMASh tag and the POI. This 
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degradation is dose dependant on FDA approved drugs and can therefore potentially 
be used in vivo. As the SMASh tag is cleaved in the absence of ASV there is a build-
up of nontagged, hence non-degron controlled, protein within the cell. This means 
that the rate of degradation is slow as, unlike other degrons discussed, is depend on 
the half-life of the POI. Offsetting this disadvantage, is the major advantage that the 
POI, in the absence of ASV, is minimally modified and unlikely to affect normal POI 
function. 
 
In summary, advancements in genome engineering allow for precise editing, rapidly 
and efficiently within multiple organisms. This has opened up the use of degrons to 
post-translationally control protein levels. Many different degrons exist, each with their 
own advantages and disadvantages. Whilst the use of degrons do not replace genetic 
knockouts, they are an excellent alternative to commonly used knockdown methods, 
such as the use of siRNA, both in vitro and in vivo. 
 
1.6 Aims 
In summary, our goal is to exploit engineered mouse GSC models and the latest 
genome editing tools to dissect the role of SOX2 and its candidate partner MYEF2.  
 
There were two primary aims: 
1. Validate and dissect the function of the MYEF2/SOX2 interaction within 
NSCs and GSCs. 
2. Assess the feasibility of the SMASh degron system to control transgenic 
and endogenous SOX2 protein levels with NSCs. 
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Chapter 2 Materials and Methods 
 
2.1 Cell culture 
2.1.1 Cell line derivation  
Mouse NSC lines  were derived from the subventricular zone of adult male C57BL/6J 
mice in a method similar to previously described225. The dissected tissue was 
collected in PBS on ice and mechanically dissociated by trituration. A second 
dissociation in accutase (Sigma) was performed for 5 min at 37oC. The sample was 
transferred to NSC wash media, filtered in a 50 µm strainer and centrifuged at 400g 
for 5 min. The cell pellet was then resuspended in NSC maintenance media and 
plated onto uncoated tissue culture plastic. This was performed by Maria Angeles 
Marques (Pollard lab). 
 
For the generation of mouse GSC (NPE) lines, NSCs were transfected with two 
sgRNAs against Nf1 and Pten. Simultaneously, constitutively active hEGFRVIII and 
GFP-luciferase piggyBac constructs were also integrated into the genome.  Cells 
were then sorted by FACS and selected for stable piggyBac integration with 4 days 
of treatment in 50 µg/ml hygromycin followed by 4 days in 5 µg/ml blasticidine. The 
bulk population was injected into an NSG mouse and a tumour was allowed to form. 
The tumour was dissected, tissue dissociated as above, and individual clones picked 
from the cell colonies formed. Clones were checked for the absence of NF1 and 
PTEN, and presence of hEGRVIII by western blotting and genotyping. (Ester 
Gangoso, Pollard lab, unpublished). 
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2.1.2 Cell line maintenance  
Established lines were maintained at 37oC and 5% CO2 in serum-free DMEM/F12 
basal media supplemented as described below and in previous studies81. Cells were 
split, onto uncoated tissue culture plastic, at a ratio of 1:4 to 1:7 using accutase 
dissociation every 2-3 days. Cryopreservation of lines was performed using 10% 
DMSO and lines stored in -80oC or liquid nitrogen for short- or long-term storage 
respectively.   
 
2.1.3 List of cell culture media 
 
Name Base media Supplements (final conc.) 
NSC maintenance media  DMEM/F12  
(Sigma) 
120 µg/ml BSA (Gibco) 
100 U/ml Penicillin (Gibco) 
100 µg/ml Streptomycin (Gibco) 
1.5 mg/ml Glucose (Sigma) 
1x NEAA (Gibco) 
0.5 X N2 (LifeTech) 
0.5 X B27 (LifeTech) 
100 µM 2-merceptoethanol (Gibco) 
10 ng/ml EGF (Peprotech) 
10 ng/ml FGF2 (Peprotech) 
2 µg/ml Laminin  (Cultrex) 
NSC wash media  DMEM/F12 150 µg/ml BSA  
100 U/ml Pen 
100 µg/ml Strep 




Table 1: Cell culture media components 
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2.1.4 Differentiation of mouse NSCs 
Neuronal differentiation 
For neuronal differentiation cells were seeded at a density of 5000 cells per cm2 in 
maintenance media with EGF removed for 3 days. At day 3 media was changed to 
maintenance media without EGF and FGF2 and cells differentiated for a further 4 
days. 
 
Astrocytic differentiation  
For astrocytic differentiation, cells were seeded at a density of 3000 cells per cm2 in 
maintenance media without EGF and FGF2, supplemented with hBMP4 (10 ng/ml, 
R&D) for 3 days. For serum induced differentiation cells were seeded at a density of 
3000 cells per cm2 in 10% foetal calf serum (Gibco) for 3 days. 
 
Oligodendrocytic differentiation  
For oligodendrocytic differentiation cells were seeded at a density of 4000 cells per 
cm2 in maintenance media without EGF and supplemented with hPDGFαα (10 ng/ml, 
R&D) for 4 days. At day 4 media was changed to maintenance media without EGF or 
FGF2 and supplemented with 30 ng/ml T3 (Sigma) and 200 µM ascorbic acid (Sigma). 
 
2.2 Derivation of genetically modified cell lines 
2.2.1 Design and construction of sgRNAs and crRNAs 
CRISPR gRNAs were designed using either MIT CRISPR design tool 
(http://crispr.mit.edu) or Desktop genetics (https://www.deskgen.com). For knock-in 
experiments gRNAs which cut, close to, but after the stop codon were selected. For 
knock-out experiments, gRNAs were designed to remove a section of the gene which 
contains a functional domain. Ideally knock-out guides are neither close to the start 
codon (in case of alternative start sites) nor at end of the coding sequence (to reduce 
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chance of obtaining a functional truncated protein). The potential off-targets of gRNAs 
were analysed with the WTSI Genome Editing tool 
(http://www.sanger.ac.uk/htgt/wge). To reduce potential off-target cleavage, gRNAs 
selected had 3 or mismatches between on-target sequence and similar sequences in 
the genome226. For the generation of sgRNA plasmids, used in section 3.2.4, single 
stranded oligos containing the 20 nt guide and 4 bp overhangs were ordered (Sigma). 
The oligos were annealed, phosphorylated and ligated into the BsaI sites of U6-
sgRNA-SpCas9-2A-GFP (Addgene PX458227). For crRNAs, used in 3.2.2, 4.2.1, and 
5.2.2, Alt-R® CRISPR-Cas9 crRNAs were ordered from IDT (Integrated DNA 
Technologies).  
 
2.2.2 List of gRNAs used 
 
Gene Function DNA sequence (5’-3’) PAM 
Mouse 
Myef2 
KI of mcherry TGCGTAATTTCAAGCATGGT TGG 
Mouse   
Myef2 

















KI mcherry and 





Table 2: List of gRNAs used 
 
2.2.3 Designing and generating targeting vectors and piggyBac 
constructs 
Myef2-mCherry targeting cassette was generated as described previously81, by Maria 
Kalantzaki (Pollard lab). Briefly, 1kbp homology arms were PCR amplified from mouse 
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NSC genomic DNA. Gibson assembly228 using standard protocols with homemade 
enzyme mixes, was then used to assemble the C’ terminal Myef2-linker-mCherry 
targeting vector. PCR amplification, to include 1 kbp of 5’ and 3’ homologous 
sequence, gave the final double stranded targeting cassette.  
 
The ssODN ultramer, used for section 3.2.2, was ordered from IDT. The ssODN 
comprises of 86 bp 5’ homology arm, HA epitope tag, stop codon, and 82 bp 5’ 
homology arm with PAM mutated from NGG>NGC. The ssODN was from the same 
strand as the crRNA (known as the PAM-strand). 
 
SMASh tag targeting vectors and piggyBac vectors were assembled using EMMA229, 
a  modular assembly system which allows for the rapid generation of vectors via a 
one-tube golden gate reaction. Briefly, each modular part was amplified via PCR from 
gDNA or plasmid DNA, with the SMASh tag obtained from Addgene #68853230, to 
generate a DNA element which is flanked by BsaI restriction sites and the specific 
positional fusion site which is generated upon cleavage by BsmBI. The fragment was 
first cloned into a part-entry vector via the BsaI sites and the library part is sequence 
verified. The one-tube golden gate reaction is then performed. This is composed of: 
the receiver vector, specific combination of library parts, BsmBI enzyme, and T4 DNA 
ligase. The final assembled plasmid is the verified by restriction enzyme digest. 
 
For the SMASh tag targeting vectors 500 bp homology arms were PCR amplified from 
the targeting vector and the product purified using a QIAquick PCR purification kit 
(Quiagen). The dsDNA was then incubated with 33% DMSO for 5 min at 95oC, then 
plunged onto ice to promote retention of single stranded DNA. The DNA is kept on 
ice until used for transfection. This was done to reduce toxicity during transfection 
(Pollard lab, unpublished observation).  
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A list of ssODNs, targeting vectors and piggyBac plasmids used is found within the 
appendix (Appendix, table 8). 
  
2.3 Transfections 
Cells were transfected with the Amaxa 4D nucleofection system (Lonza). The 
transfection solution SG (Lonza) was used with the program DN100.  For section 
3.2.4, 1.5x106 cells were pre-mixed with 600 ng of targeting cassette and 1 µg of each 
sgRNA/Cas9 plasmid in 100 µl SG buffer.  For section 3.2.2 and chapter 5, 3x105 
cells were pre-mixed with 12.4 µg of Cas9/sgRNA ribonucleprotein and 300 ng of 
targeting cassette or 1.5 µg of ssODN (IDT) in 20 µl SG buffer.  The  assembly of 
Cas9/sgRNA complex was performed as previously described185. Briefly, 2.2 µg of 
tracrRNA (IDT) and 1.2 µg of crRNA (IDT) were annealed by heating to 95oC for 5 
min and gradually cooled to 25oC at a rate of 0.1oC/sec. 10 µg of recombinant Cas9 
protein (expressed and purified from Addgene, #53261) was mixed with the annealed 
crRNA/tracrRNA at room temperature for 10 min allowing the ribonucleoprotein 
complex to form. For piggyBac integrations, 3x105 cells were pre-mixed with 300 ng 
of expression plasmid, 500 ng of hyPBase expression plasmid and 300 ng of pCAG-
Tet-On® 3G plasmid.  
 
After transfection cells were plated into uncoated tissue culture plastic and allowed to 
recover. Targeted cells were then enriched by BD FACSAriaTM II (BD bioscience) or 
treatment with 1 µg/ml puromycin for 7 days. 
 
2.3.1 Colony picking  
Single cells were deposited into 96-well plates using BD FACS AriaTM II cell sorter. 
After 2 weeks approximately 15-30 colonies per 96-well plate were obtained. Colonies 
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were manually transferred using 5 µl of accutase with a 20 µl pipette. Clones were 
checked for correct targeting via ICC, PCR and western. 
 
2.3.2 PCR genotyping  
Cells from a confluent 96-well were incubated for 2 hrs at 55oC in 20 µl of lysis buffer 
(0.2 µg/ml proteinase K, 0.45% NP40, 0.45% Tween20 and 1x LongAmp PCR buffer). 
Samples were then heated to 95oC for 10 min. Alternatively, DNA was isolated by 
DNeasy blood and tissue kit (Qiagen) according to manufacturer’s instructions. 
Genotyping primers were designed outside of the 5’ and 3’ homology arms. For 
chapters 3 and 4 LongAmp® Taq (NEB) DNA polymerase was used, whilst 
PrimerSTAR® MAX was use for chapter 5. The following PCR conditions were used. 
 
Knock-in of HA to Myef2 
Step Temperature (oC) Time (sec) Cycles 












Final extension 72 300 1 
Storage 4 ∞ 1 
 
Knock-in of mCherry to Myef2 
Step Temperature (oC) Time (sec) Cycles 












Final extension 72 300 1 
Storage 4 ∞ 1 
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Knock-out of Myef2 
Step Temperature (oC) Time (sec) Cycles 












Final extension 72 300 1 
Storage 4 ∞ 1 
 
Knock-in of SMASh to Sox2 
Step Temperature (oC) Time (sec) Cycles 
Initial denaturation 94 120 1 
Denaturation 
Annealing (start-final) 







(dropped 1oC per cycle 
for 10 cycles prior to 













Final extension 72 300 1 
Storage 4 ∞ 1 
 
2.3.3 List of genotyping primers  
 
Locus Function Forward (5’-3’) Reverse (5’-3’) 






















Table 3: Genotyping primers 
   
  45 
2.4 Immunocytochemistry 
Cells were fixed in 4% PFA and blocked in blocking solution (PBS with 0.1% BSA and 
3% goat serum). For intracellular epitopes, samples were permeabilised with PBST 
(PBS plus 0.1% triton-x) between the fixation and blocking step. Samples were 
incubated with primary antibody overnight at 4oC. After three washes, samples were 
incubated with the respective goat secondary antibody (Invitrogen, 1:1000) for 1 hr. 
Nuclear counter stain DAPI was used at a final concentration of 1 µg/ml. To acquire 
images, either a Nikon TiE microscope or a Zeiss fluorescence microscope was used.  
 
2.4.1 List of primary and secondary antibodies used for ICC 
 
Antigen Species Subtype Dilution Manufacture 
mCherry Rabbit IgG 1/500 Abcam (ab167453) 
HA Mouse IgG1 1/100 Cell signalling (2367) 
SOX2 Rabbit IgG 1/100 Abcam (ab92494) 
BLBP Rabbit IgG 1/200 Santa Cruz (sc30088) 
NESTIN Mouse IgG1 1/500 R&D (mab1259) 
GFAP Rabbit IgG 1/1000 Sigma (G9269) 
TUJ1 Mouse IgG2a 1/500 Biolegend (801202) 
MBP Rat IgG 1/20 Biorad (aa8287) 
MYEF2 
(non-specific) 
Rabbit IgG 1/200 Sigma (HPA004883) 
MYEF2 
(non-specific) 
Rabbit IgG 1/200 Sigma (AV32738) 
MYEF2  
(non-specific) 
Rabbit  IgG 1/200 Proteintech (16051-1-AP) 
 
Table 4: List of antibodies used for ICC 
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2.5 Western immunoblotting  
For immunoblotting of tissue samples, a male Bl6 adult mouse was sacrificed and 
relevant tissues collected. Dissection of the individual brain regions was performed 
by Maria Angeles Marques (Pollard lab). The tissues suspended in protease inhibitor 
supplemented lysis buffer (25 mM Tris-HCl pH8, 150 mM NaCl, 1% NP-40, 1% 
NaDoc, 1% SDS, 20mM NaF and 2.5 mM Na3VO4) and manually dissociated through 
a syringe. Samples were vortexed and incubated on ice for 20 min. Lysates were then 
cleared by centrifugation at 13000 rpm for 15min at 4oC. 
 
For in vitro samples, cell pellets were lysed and incubated for 30 min at 4oC in lysis 
buffer (150 mM NaCl, 20 mM TrisHCl, 1% NP40, 2 mM EDTA, 1 mM NaF, 0.1% SDS) 
freshly supplemented with complete protease inhibitors (Roche). The lysate was then 
cleared by centrifugation at 13000 rpm at 4oC for 15 min. Lysates were then quantified 
Pierce Assay (Thermo Fisher) according to the manufacturer’s instructions. Samples 
were mixed in loading buffer (LDS with 20 mM DTT) and heated to 95oC for 5 min. 
Electrophoresis was performed on polyacrylamide gels using the BioRad system and 
Precision plus proteinTM dual Xtra ladder (BioRad). Semi-dry trans-blot Turbo transfer 
system (BioRad) was used to transfer proteins onto 0.45 µM Immobilon-P PVDF 
membrane (Millipore). 
 
Membranes were blocked with 5% milk in TBST for 1 hr at room temperature. 
Membranes where then incubated with the relevant dilution of primary antibody in 
TBST with 5% milk overnight at 4oC. Washes with TBST were performed at room 
temperature and membranes were incubated with relevant HPR-conjugated 
secondary antibodies (Novex) at a dilution of 1:10000 in TBST/5% milk for 1 hr at 
room temperature. Membranes were then washed with TBST and developed using 
either homemade ECL or immobilon ECL (Millipore).  
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2.6 Immunoprecipitations 
For immunoprecipitation experiments cells were lysed in protease inhibitor 
supplemented lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% NP-40, 5% 
glycerol, 1 mM DTT, 2 mM MgCl2, 10 mM β-glycerophosphate, 10 mM sodium 
pyrophosphate, 1 mM NaF and 2 mM Na3VO4). Lysates were incubated with 250 units 
per ml of benzonase (Sigma) for 30 min at 4oC, then cleared by centrifugation. After 
quantification 0.8 mg–1.5 mg of protein was incubated with magnetic beads 
conjugated to the relevant primary antibody overnight at 4oC shaking at 1200 rpm. 
Beads were then washed in wash buffer (lysis buffer without protease inhibitors and 
NP40). Sample was then mixed with 2x loading buffer and heated to 95oC for 5 min. 
 
2.7 Mass spectrometry  
For mass spectrometry, samples were lysed at a concentration of 20x106 cells per ml 
of lysis buffer (20 mM HEPES pH7.5, 150 mM NaCl,1% triton X-100, 2 mM MgCl2, 1x 
protease inhibitor cocktail and 250 units/ml benzonase) for 30 min at 4oC. Lysates 
were then cleared by centrifugation at 13000 rpm for 15 min at 4oC. Samples were 
flash frozen in liquid nitrogen. This was performed by Carla Blin.  
 
Samples were then sent to collaborator Alex Von Kriegsheim. 500 µl of cleared lysates 
were incubated with PierceTM anti-HA magnetic beads for 2 hrs. Samples were then 
processed as previously described231. After obtaining the filtered list, it was analysed 
within Cluego in cytospace232. A p value of 0.05 with GO biological processes was 
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Application Dilution Manufacture 
V5 Mouse IgG2ak IP 50 µl per IP MBL 
(M167-11) 
V5 Mouse IgG2b WB 1/1000 eBioscience 
(14679682) 
MYEF2 Rabbit IgG WB 1/1000 Sigma  
(AV32738) 
SOX2 Mouse IgG2a IP 
WB 




HA Rabbit IgG IP 
WB 




GAPDH Mouse IgG1 WB 1/5000 Ambion 
(AM4300) 
SOX8 Rabbit IgG WB 1/1000 Abcam 
(ab104245) 
SOX9 Rabbit IgG WB 1/1000 Millipore 
(ab5535) 
OLIG2 Rabbit IgG WB 1/3000 Millipore 
(ab9610) 






IP 10 µl per IP Chromotek 
(gtma-20) 
pH3 Ser10 Rabbit IgG WB 1/1000 Cell signalling 
(3458) 
HA Mouse IgG1 Mass 
spec 






IgG WB 1:500 Cell signalling 
(3777) 
 
Table 5: List of antibodies used for western blotting and immunoprecipitations 
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2.8 Flow cytometry 
Cells were collected using accutase and resuspended in PBS with 0.1% BSA. A dead 
live marker of DAPI, DRAQ7 or TO-PRO-3 was used. Samples were analysed using 
a BD LSR Fortessa cell analyser (BD biosciences) and data analysis was performed 
with FlowJo analysis software (TreeStar). 
 
2.8.1 Hoechst 3342 staining and cell cycle analysis 
1x106 mouse NS cells were stained with Hoechst 33342 (Tocris), in 1 ml of NSC 
maintenance media, at a final concentration of 5 µg/ml of Hoechst for 90 min at 37oC. 
Cell cycle analysis was then performed using FlowJo V10 using the univariate model. 
 
2.9 Cellular assays 
2.9.1 Proliferation rate assays 
For analysis of proliferation rates cells were seeded at a density of 5000 cells per cm2. 
For BMP sensitivity assays, cells were seeded at a density of 3000 cells per cm2. 
Samples were then incubated with 10 µM EdU for either 2 hrs or 24 hrs and stained 
with the Click-iT EdU alexa 647 assay kit (Life technologies) according to the 
manufacturer’s instructions.  
 
2.9.2 Confluency curves 
For confluency curve analysis cells were seeded at 5000 cells per cm2, in triplicate 
wells, and confluence analysed by the Incucyte live cell imaging system (Essen 
Bioscience). This assay measures the occupied area of the dish (cell confluency) 
acting as a read out of cell proliferation, provided cells do not undergo large alterations 
in morphology.   
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2.9.3 Colony formation assays 
Cells were seeded at density of 10 cells per cm2 in 10mm dishes and colonies allowed 
to form for 10-15 days. Fixed cells were stained with 1% methylene blue and colonies 
counted manually and using the Fiji ColonyArea233 plugin.  
 
For the de-differentiation assays, cells were seeded at a density of 300 or 500 cells 
per cm2  in astrocytic differentiation media for 3 days. After 3 days, media was changed 
to NSC maintenance media for 10 days. 
 
2.10 Nocodazole treatment 
Cells were treated with nocodazole (sigma) at a final concentration of 50 ng/ml for 6 
hrs in NSC maintenance media. 
 
2.11 Treatment with HCV NS3/4A serine protease inhibitor 
For experiments in Chapter 5, cells were treated with ASV (Cayman Chemical), 
dissolved in DMSO, at the relevant concentration for the specified time. Samples were 
supplemented with DMSO, so the final DMSO concentration of all samples was 0.3%. 
 
2.12 Live imaging 
Time-lapse images were taken on Nikon TIE microscope at 37oC and 5% CO2. 
Images were taken every 3 min with a 60X oil immersion objective.  
 
2.13 Intracranial transplantation  
2x105 cells, resuspended in 2 µl of NS maintenance media, were transplanted into the 
frontal cortex of adult male NSG mice (aged 6-8 weeks). A stereotaxic frame was 
used and cells were injected into the coordinates 1 mm rostral,  2mm lateral to the 
Bregma and 2.5 mm deep234. Mice were monitored for tumour formation through 
luciferase bioluminescent imaging (IVIS spectrum imager, PerkinElmer) and the 
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health of the mice was continually monitored. At the onset of symptoms, mice were 
culled, and tumours were imaged using a leica M165 FC stereomicroscope. Injections 
were performed by Steven Pollard and Neza Alfazema. Monitoring and 
bioluminescent imaging was performed by Neza Alfazema and the SCRM animal unit.   
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Chapter 3 MYEF2, a brain enriched SOX2 interactor 
 
3.1 Introduction 
SOX2 is a core transcription factor of NSCs and GSCs, with the downregulation of 
SOX2 impairing the proliferation and tumour formation capacity of GSCs84,119–121. Due 
to its role in glioblastoma, SOX2 is a clear therapeutic target. However, targeting 
transcription factors with small molecules is difficult. Identification of key SOX2 
interactors may provide an alternative strategy, with the interactor itself or the 
interaction between SOX2 providing novel therapeutic targets. Also, SOX2 has an 
important role in many tissue stem cells112; hence, there is a need to determine if there 
are neural or NSC specific mechanisms that could be targeted, without affecting other 
tissues.  
 
To identify interactors which are most likely to be functionally relevant, Pooran Dewari 
(Pollard lab) recently used CRISPR/Cas9 to epitope tag several SOX members. As 
SOX factors are DNA binding proteins, we specifically looked at the on-chromatin 
interactors of several SOX factors, to increase the probability of obtaining functionally 
relevant interactors. The well-established mass spectrometry methods, ChIP-MS235 
and RIME236, crosslink DNA-protein complexes in-cellulo prior to immunoprecipitation 
allowing for stringent recovery under harsh conditions and enrichment for on-
chromatin interactions. RIME also includes an initial nuclear isolation step prior, 
between crosslinking and immunoprecipitation steps, leading to the identification of 
nuclear only interactors. However, both ChIP-MS and RIME often have contamination 
issues, from the immunoprecipitation (IP) antibody, and are incapable of actually 
distinguishing between on-chromatin and off-chromatin interactions. SICAP237, 
selective isolation of chromatin associated proteins, combined with mass 
spectrometry can overcome these issues. In SICAP-MS, as in ChIP-MS and RIME, 
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DNA-protein complexes are crosslinked in-cellulo and the protein of interest and its 
interactors are isolated under ChIP conditions. In SICAP-MS, unlike ChIP-MS and 
RIME, DNA is then labelled with biotinylated nucleotides. This allows for the removal 
of the IP antibody and the isolation of on-chromatin only interactors by streptavidin 
isolation of the DNA.   
 
3.1.1 Epitope tagging of endogenous sox factors 
The quality of mass spectrometry data is affected by the availability of high-quality 
antibodies suitable for IP of the protein of interest. The generation of an epitope 
tagged fusion protein is one manner to overcome the absence of suitable antibodies. 
Establishment of nucleofector mediated delivery of a ssODN repair template and 
recombinant Cas9 pre-complexed with synthetic crRNA/tracrRNA (RNP), enabled for 
efficient scalable epitope tagging of endogenous loci in NSCs185. From this method, 
V5 knock-in efficiencies of 21% (SOX2), 30% (SOX3), 14% (SOX8) and 26% (SOX9) 
were obtained for sox factors in the mouse GSC line, IENS, without prior selection185. 
Clonal lines for each sox factor were subsequently derived and used for mass 
spectrometry experiments (Pooran Dewari, Pollard lab).  
 
3.1.2 SICAP mass spectrometry of V5 tagged SOX factors in mouse GSC 
lines 
SICAP-MS237 was performed on the endogenously V5 tagged mouse GSC lines sox2-
V5, sox3-V5, sox8-V5 and sox9-v5 by Pooran Dewari, German Monogarov and 
Jeroen Krijgsveld. All four of these SOX factors are highly expressed within the mouse 
GSC line, and sox2, sox3 and sox9 are known regulators of NSCs/NPCs104. The 
degree of functional redundancy between SOX factors within the in vivo tumour 
environment is unknown, hence SICAP-MS was performed on all four SOX factors. 
The data was filtered to remove histones, ribosomal proteins (RPL/RPS), 
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heterogenous nuclear ribonucleoproteins (HNRNPs) and splicing factors (SRSF), 
which are common contaminants of mass spectrometry experiments, using 
Perseus238. Many on-chromatin interactors were identified for each SOX factor, 
including several which were common between all four SOX factors (Fig 3.1, 
unpublished data provided by Pooran Dewari, German Monogarov and Jeroen 
Krijgsveld). This included MYEF2, which was the only common interactor of all four 
SOX factors after CRAPome filtering239.  
 
3.1.3 Co-immunoprecipitation confirms the interaction of MYEF2 and 
SOX2 
In SICAP-MS protein-DNA complexes are crosslinked, chromatin sonicated to 200-
500 bp fragments, protein of interest is immunoprecipitated and DNA bound 
complexes are isolated. Due to this, SICAP-MS cannot distinguish between protein 
interactors of the protein of interest and indirect interactors which may be identified 
as they reside on the same short DNA fragment.  
 
In order to determine if MYEF2 is a protein interactor of SOX factors, co-
immunoprecipitations were performed on sox2-V5, sox3-V5, sox8-V5 and sox9-V5 
mouse GSC lines. Immunoprecipitations for two other TFs,  olig2-V5 and foxk2-V5, 
were also performed as anticipated negative controls. Using V5 magnetic beads each 
V5 tagged SOX protein was immunoprecipitated, with the untagged parental line 
providing an excellent negative control for the V5 immunoprecipitation. Samples were 
then checked for the co-immunoprecipitation of MYEF2. In the absence of in-cellulo 
crosslinking, used in SICAP-MS, MYEF2 co-precipitated with SOX2; however, this 
was not the case for SOX3, SOX8 or SOX9. MYEF2 did not co-precipitate with 
predicted negative controls OLIG2 and FOXK2 (Fig 3.2.A). These data indicate that 
MYEF2 may interact closely, perhaps even directly, with SOX2, while the interaction 
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between SOX3, SOX8 and SOX9 is likely to occurs indirectly through their co-
localisation in the same chromatin regions.  
 
The interaction between SOX2 and MYEF2 was also observed in the 
immunoprecipitation of native SOX2 in a mouse NSC line. The interaction was seen 
in both the absence and presence of ethidium bromide (EtBr). This suggests that the 
interaction between SOX2 and MYEF2 is not DNA dependant240, though further work 
is required to determine this, as this particular interaction may have not been disturbed 
by the distortions mediated by EtBr. In fact, a higher amount of MYEF2 could be seen 
with ethidium bromide. It is possible that the distortion cause by ethidium bromide 
increases the exposure the MYEF2 antibodies epitopes, as the amount of SOX2 
precipitated appears similar between the samples (Fig 3.2.B). Finally, the presence 
or absence of NaF, a serine/threonine phosphatase inhibitor, did not alter the 
interaction between SOX2 and MYEF2. In the absence of serine/threonine inhibitors 
it is likely that  serine and threonine phosphorylation will be globally lost, suggesting 
serine/threonine phosphorylation is not required for the interaction of SOX2 and 
MYEF2. However, it is necessary to confirm the loss of phosphorylation before a solid 
conclusion can be drawn (Fig 3.2.C).  
 
To conclude, MYEF2 was initially identified as a SOX factor interactor through SICAP-
MS. The interaction between SOX2 and MYEF2 occur through the same protein 
complex, perhaps even directly, while the interaction of MYEF2 and SOX3, SOX8 and 
SOX9 most like occurs indirectly through co-localisation in the same chromatin 
regions. Exploration of the function of MYEF2, and the significance of its interaction 
with SOX2, will form the basis of my next two chapters. 
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Figure 3.1 | SICAP mass spectrometry of V5 tagged SOX factors in mouse GSC lines 
SICAP mass spectrometry data of interactors identified for SOX2-V5, SOX3-V5, SOX8-
V5 and SOX9-V5 in mouse GSC cell lines. Data was filtered to remove histones, 
ribosomal proteins (RPL/RPS), heterogenous nuclear ribonucleoproteins (HNRNPs) and 
splicing factors (SRSF). Data shown is before CRAPome filtering. N=1. Data for this figure 
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Figure 3.2 | Co-immunoprecipitation of MYEF2 associated with V5 tagged SOX2 and 
native SOX2 
(A) Co-IP of proteins associated with V5 tagged proteins in endogenously tagged mouse 
GSC lines (IENS). Sox2, sox3, sox8, sox9, olig2 and foxk2 were tagged with V5 as 
described185 by Pooran Dewari. Extracts from each line were made with benzonase. 
Immunoprecipitation against V5 was performed using V5 beads. IPs were blotted for V5 
and for the co-IP of MYEF2. Parental untagged line was included as a negative control 
for the IP. N=1 (B) IP of native SOX2 in mouse NSCs in the presence or absence of 
ethidium bromide. Extracts were made from untagged mouse NSC samples (ANS4) with 
benzonase. Samples were immunoprecipitated with magnetic protein G beads conjugated 
to anti-SOX2 or anti-IgG antibodies, either in the presence or absence of ethidium 
bromide. IPs were then blotted for SOX2 and the co-IP of MYEF2. N=1 (C) IP of native 
SOX2 in mouse NSCs in the presence or absence of NaF. Extracts were made from 
untagged mouse NSC samples (ANS4) with benzonase either in the presence or absence 
of NaF. Samples were immunoprecipitated with magnetic protein G beads conjugated to 
anti-SOX2 or anti-IgG antibodies, either in the presence or absence of ethidium bromide. 
IPs were then blotted for SOX2 or co-IP of MYEF2. N=1.All data in this figure was provided 
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3.2 Results 
3.2.1 MYEF2 is a testis and brain enriched protein  
MYEF2 was first identified as a single stranded DNA binding protein from a phage 
based screen to identify proteins, derived from a 15 day postnatal mouse brain cDNA 
library, that can bind to a single stranded probe generated from the myelin basic 
protein (mbp) proximal promoter region MB1132. The proposed sequence of myef2 
from this initial study was a N-terminal truncated version. Subsequently, the full length 
myef2 locus was shown to encode a ~60 kDa protein, proposed to have three RRM 
RNA/single stranded DNA binding domains241. Consistent with our SICAP-MS data, 
MYEF2 has been proposed to be a nuclear localised protein242. Human RNA-seq data 
has shown that MYEF2 transcripts are enriched in the brain and testes (Fig 3.3.A, 
data sets taken from the human protein atlas242). We therefore performed western 
blotting to determine in which tissues MYEF2 is found. This confirmed that MYEF2 is 
enriched at the protein level in the brain and testes of adult mice (Fig 3.3.B). Within 
the brain, MYEF2 is expressed throughout all core regions tested and was not 
enriched in the subventricular zone, which harbours the NSCs (Fig 3.3.C). This brain 
enriched localisation of MYEF2 suggests it could have a neural-specific function and 
contributed to its potential as an interesting specific target for GBM. We therefore 
began characterising the expression and functions of this understudied SOX 
interaction partner. 
 
3.2.2 Generation of epitope tagged Myef2 by CRISPR-Cas9 
To study the function of MYEF2, several commercial antibodies were tested on both 
Myef2 wild-type mouse GSCs (IENS) and Myef2 knockout GSCs (IENS) I generated 
(Fig 3.4.A - 3.4.D). By ICC, these antibodies gave a strong signal, though this was not 
always nuclear (MYEF2 antibody 3). Signal was retained in Myef2 knock-out GSC 
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lines (IENS), highlighting that the tested commercial antibodies are unsuitable for ICC 
(Fig 3.4.E). One of these commercial antibodies detects MYEF2 by western, but also 
identifies additional unspecific proteins. 
 
To overcome these limitations, a C-terminal epitope tag knock-in mouse NSC line was 
generated. In a wild-type mouse NSC line a single copy of the epitope tag HA was 
knocked into the endogenous locus of Myef2 using the RNP based system185 (Fig 
3.5.A). Attempts to tag MYEF2 with V5 were unsuccessful. From the bulk transfected 
population single cells were sorted into 96 well plates by FACS and subsequent 
colonies were screened for HA staining. Of the 84 colonies screened, one clone was 
positive for HA staining (Fig 3.5.B). PCR-genotyping, and sequencing of the relevant 
PCR product, confirmed that in this clone, one allele of Myef2 was targeted (Fig 3.5.C, 
sequencing data not shown) and a band could be observed at the expect molecular 
weight when immunoblotting against HA (Fig 3.5.D). The HA staining observed was 
exclusively nuclear. This nuclear staining is in line with current data and the 
identification of MYEF2 as an on-chromatin partner of SOX2. 
 
3.2.3 Reverse co-immunoprecipitation confirms the interaction of SOX2 
and MYEF2 
With a tagged Myef2 NSC line to hand, we were able to next confirm the interaction 
of MYEF2 and SOX2 co-immunoprecipitation experiments, in the reverse order to that 
previously performed. MYEF2-HA was immunoprecipitated and the interacting 
complexes checked for co-interaction of SOX factors and OLIG2.  
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Figure 3.3 | MYEF2 is testis and brain enriched 
(A) RNA-seq data of MYEF2 protein coding transcripts per million (TPM) in various 
tissues. Data taken from the human protein atlas project242. (B) Western blotting against 
MYEF2 on tissue taken from various organs of an adult male mouse (C57BL/6J). N=1. 
(C) Western blotting of MYEF2 on samples taken from various regions of the brain of an 
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Figure 3.4 | Mouse GSC (IENS) Myef2 knockout and suitability of commercial 
antibodies 
(A) Experimental method to knockout exon 2 of Myef2. Cells were transiently transfected 
with a plasmid encoding both Cas9-P2A-GFP and sgRNAs. Targeted cells were then 
enriched by FACS based on transient GFP expression. (B) Schematic of Myef2 locus. 
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the intronic regions flanking either side of exon 2. PCR genotyping primers were designed 
outside of the cut sites and are depicted as F1 and R1. (C) Representative genotyping of 
IENS clones with primers F1 and R1. Sizes of expected wild-type and knockout bands are 
highlighted. (D) Western blotting of the two clones identified as knockouts by genotyping. 
(E) ICC of Myef2 wild-type and Myef2 mutant lines with three commercial antibodies. 
Antibody 1 corresponds to catalogue number HPA004883, antibody 2 to catalogue 
number 16051-1-AP and antibody 3 to catalogue number AV32738. Scale bar: 50 µm. 
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Figure 3.5 | Generation of epitope tagged Myef2 by CRISPR-Cas9 
(A) Schematic of ssODN repair template and targeted Myef2 locus. CRISPR gRNA, which 
cuts in the 3’UTR near the stop codon, is depicted by a yellow triangle. PCR genotyping 
primers were designed outside of the homology arms and are depicted as F1 and R1. (B) 
Representative ICC of wild-type parental line and the targeted clone positive for HA 
staining. Scale bar: 50 µm. (C) Genotyping of the HA positive clone with primers F1 and 
R1. Expected sizes of wild-type and knock-in bands are shown. (D) Western 
immunoblotting against HA and GAPDH on extracts from the wild-type parental line and 
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As previously observed (Fig 3.2), in the absence of in-cellulo crosslinking, an 
interaction between MYEF2 and SOX2 was confirmed, although the result is less 
striking than previous experiments (Fig 3.6 and Fig 3.3). However, perhaps 
interestingly, we did not see interaction between with either SOX8 or SOX9. Due to 
the failure of the SOX3 antibody used to give a signal, information on the interaction 
between SOX3 and MYEF2 could not be derived from these experiments (Fig 3.6). 
Overall, this data supports the interaction of MYEF2 and SOX2 within the same 
protein complex in mouse NSCs, whereas interactions with other SOX members may 
be rather indirect occurring from co-localisation on the same chromatin regions. 
 
3.2.4 Endogenous knock-in of mCherry to the Myef2 locus 
Fluorophores such as GFP and mCherry are widely used for the study of living cells 
by microscopy and flow cytometry. To further explore the levels and localisation of 
MYEF2 we used a plasmid based CRISPR/Cas9 method and knocked in a linker-
mCherry encoding sequence to the endogenous myef2 locus of mouse NSCs (Fig 
3.7.A and Fig 3.7.B). By FACS, mCherry positive cells were single cell sorted into 96 
wells from a 0.2% mCherry positive population. From the 7 clones which were PCR 
genotyped, one clone (A8) showed mono-allelic targeting of the Myef2 locus whilst 
retaining the other wild-type allele. Two other clones had mono-allelic knock-in of 
mCherry, but a large deletion in the other Myef2 allele was observed (Fig 3.7.C). 
Western blotting against MYEF2 in these two clones gave bands at the expected sizes 
of both MYEF2-mCherry fusion protein and MYEF2 (data not shown). The normal size 
of the MYEF2 band suggest the genetic deletion has not dramatically affected the C-
terminal of the protein, although sequencing is required to show the exact deletion. 
These two clones were not taken forward. ICC of clone A8 showed nuclear mCherry 
expression, as expected for the MYEF2-mCherry fusion protein (Fig 3.7.D). Western 
blotting of A8 detected a mCherry band of the expected size (~90 kDa) and blotting 
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using an antibody against MYEF2 identified bands at the predicted size of MYEF2 
(~60 kDa) and MYEF2-mCherry (~90 kDa), supporting this is a heterozygous clone 
as observed by genotyping (Fig 3.7.E). 
 
3.2.5 MYEF2-mCherry levels are retained under differentiation cues 
Treatment of NSCs with BMP4/FGF2 or BMP4 promotes entry of NSCs into the 
quiescence (late G1) and dormancy (G0) respectively, while serum promotes exit from 
the cell cycle (Maria Angeles Marques, unpublished). When treated with BMP4 or 
serum for 3 days the levels of SOX2-mCherry drops dramatically (Fig 3.8). This drop 
is homogenous throughout the population (Fig 3.8.B) with levels dropping to 20% and 
7%, correspondingly, of those observed in growth conditions (Fig 3.8.C). The 
treatment of sox2-mCherry NSCs with BMP4/FGF2 for 3 days has a more 
heterogenous effect on the cells. From live microscopy, in many cells the expression 
of SOX2-mCherry drops dramatically, though it is retained in a fraction of the 
population. The morphology of cells appears similar throughout the population (Fig 
3.8.A). This heterogeneity can be more clearly seen from flow cytometry data. While 
the average SOX2-mCherry level within the BMP4/FGF2 treated population is 50% of 
that in growth factors (Fig 3.8.C) the expression level of SOX2-mCherry in individual 
cells varies (Fig 3.8.B).  
 
Unlike SOX2, MYEF2-mCherry can be seen by live microscopy in all conditions (Fig 
3.8.A). The levels observed are similar to those in growth conditions, with a marginal 
reduction occurring in BMP4 and serum (Fig 3.8.C). The range of MYEF2 expression 
within in Myef2-mCherry cells in all conditions is similar, with the population showing 
a similar distribution as to that observed in proliferative conditions (Fig 3.8.B). A small 
number of mCherry negative cells can be seen in all conditions, though amounts are 
higher in BMP4/FGF2 and serum treated cells (Fig 3.8.B). MYEF2 therefore is not lost 
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upon differentiation and therefore could have SOX2 independent roles. It should be 
noted that the generation of a MYEF2-mCherry fusion protein may alter the normal 
behaviour of MYEF2. Complementary methods, such as western blotting and qPCR, 
would circumvent potential fusion protein caveats, but are limited to observations on 
the population as a whole, rather than for individual cells. 
 
3.2.6 Nuclear MYEF2 is retained upon differentiation  
Adherent NSCs are tripotential, capable of differentiating into neurons, astrocytes and 
oligodendrocytes243. The clonal NSCs lines of Myef2-mCherry and Myef2-HA retained 
this tripotential capability (Fig 3.9 and Fig 3.10). In line with previous observations (Fig 
3.7) nuclear MYEF2 is retained in GFAP positive astrocytic like cells, at a level similar 
to that of undifferentiated NSCs (Fig 3.9.A and Fig 3.10.A). Differentiation to neurons 
and oligodendrocytes gave more heterogenous populations, with ß-III tubulin (Tuj1) 
positive neurons and MBP positive oligodendrocytes also retaining nuclear MYEF2 
expression at levels comparable to undifferentiated NSC (Fig 3.9 and 3.10).  
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Figure 3.6 | Co-IPs using Myef2-HA confirm the interaction with SOX2 
Co-immunoprecipitation of proteins associated with HA tagged MYEF2 in mouse myef2-
HA NSC line using anti-HA conjugated magnetic beads. Untagged wild-type parental line 
provides negative control for the HA IP. Between 0.8-1.2 mg of protein extract, pre-treated 
with benzonase, was used per co-IP. After the IP, blotting against HA and native SOX2, 
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Figure 3.7 | Endogenous knock-in of mCherry to the Myef2 locus 
(A) Experimental method to endogenously knock-in mCherry to Myef2. Cells were 
transiently transfected with a mCherry targeting cassette (provided by Maria Kalantzaki, 
Pollard lab) and plasmids encoding both Cas9-P2A-GFP and sgRNAs. Targeted cells 
were then selected by FACS based on mCherry expression. (B) Schematic of dsDNA 
mCherry targeting cassette and the targeted Myef2 locus. CRISPR sgRNAs, which cut in 
the 3’UTR near the stop codon, are depicted by yellow triangles. 2 different sgRNAs were 

























































   
  69 
are depicted as F1 and R1. (C) Genotyping of mCherry positive sorted clones with primers 
F1 and R1. Expected sizes of wild-type and knock-in bands are shown. (D) 
Representative ICC of wild-type parental line and the targeted clone A8. Scale bar: 50 
µm. (E) Western immunoblotting against mCherry, MYEF2 and GAPDH on extracts from 
the wild-type parental line and the clone A8.  
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Figure 3.8 | MYEF2-mCherry levels are retained under differentiation cues 
(A) Representative microscopy images of live mouse NSCs treated for 3 days in complete 
media with growth factors, BMP4 and FGF2, BMP4 or 10% serum. (Bulk sorted Sox2-
mCherry NSC line provided by Pooran Dewari, Pollard lab). Scale bar: 50 µm, n=3 
biological replicas. (B) Representative flow cytometry data of lines treated for 3 days in 
complete media with growth factors, BMP4 and FGF2, BMP4 or 10% serum. Parental 
wild-type line provided gating controls. Data is represented on a linear scale. n=3 
biological replicas. (C) Flow cytometry data of lines treated for 3 days in complete media 
n= 3 biologivl replicas 
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with growth factors, BMP4 and FGF2, BMP4 or 10% serum. Due to the varying levels of 
autofluorescence between conditions data is normalised to parental wild-type line in the 
corresponding treatment. Graph shows mean mCherry intensity ± SD from 3 biological 
replicas. 
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3.2.7 MYEF2 does not bind to mitotic chromosomes  
During mitosis major changes occurs within the cell. These include a general 
repression in transcription, nuclear envelope disassembly, histone phosphorylation  
and chromatin reorganisations including changes to 3D topology and its 
condensation244. These chromosomal changes are associated with a general 
displacement of transcription factors from chromatin. Recently, however, it has been 
shown that several transcription factors, including GATA1245, FOXA1246 and 
ESRRB247, remain bound to many of their interphase targets on the mitotic chromatin. 
This feature is known as mitotic bookmarking and is thought to be involved in rapid 
post-mitotic reactivation of genes.  
 
Live cell imaging of SOX2 fusion proteins has shown that SOX2 is bound to the mitotic 
chromatin in embryonic stem cells and there is some evidence this is occurring, at 
least in part, through the interphase targets of SOX2248–250. Through live cell imaging 
of several NSC Sox2 fusion lines we have observed that SOX2 is retained on the 
mitotic chromatin in NSCs (Kalantzaki, Pollard lab, unpublished). 
 
This was first observed in our lab by Maria Kalantzaki using Sox2-mCherry NSC lines 
(Pollard lab, data not shown) and recently confirmed in both a Sox2-GFP NSC line 
(Charles Williams, Pollard lab, data not shown) and an independent Sox2-mCherry 
NSC line (Fig 3.11.A). It remains unclear if this retention in NSCs is occurring through 
specific interphase sites and has bookmarking roles. 
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Figure 3.9 | Nuclear MYEF2-mCherry is retained upon differentiation 
Representative ICC images of the mouse NSC Myef2-mCherry line A8 differentiated to 
(A) GFAP positive astrocytes (B) Tuj1 positive neurons and (C) MBP positive 
oligodendrocytes. Undifferentiated cells provided ICC control, with all cells observed in 
focus expressing MYEF2-mCherry. All cells positive for differentiation markers (GFAP/ 
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Figure 3.10 | Nuclear MYEF2-HA expression is retained upon differentiation 
Representative ICC images of the mouse NSC Myef2-HA line differentiated to (A) GFAP 
positive astrocytes (B) Tuj1 positive neurons and (C) MBP positive oligodendrocytes. 
Undifferentiated cells provided ICC control, with all cells observed in focus expressing 
MYEF2-HA. All cells positive for differentiation markers (GFAP/ Tuj1/ MBP) were also 
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As fixation with paraformaldehyde can lead to artificial exclusion of factors from the 
mitotic chromatin249, live cell imaging of Myef2-mCherry NSC line was performed to 
asses if, like SOX2, MYEF2 may be a bookmarking factor. MYEF2-mCherry was not 
observed on the mitotic chromatin (Fig 3.11.B). Instead MYEF2 is clearly absent from 
mitotic chromosomes, and is present diffusely throughout the cell, then returning to 
the nucleus once the nuclear envelop reforms (Fig 3.11.B). This suggests MYEF2 is 
not a mitotic bookmarking factor and becomes dissociated from SOX2 in mitosis.  
 
From live cell imaging the MYEF2 signal appears weaker in mitotic cells. It is, 
however, unclear if this observed drop in levels of MYEF2 during mitosis is due to the 
nuclear envelope disassembly in mitosis, and hence a more diffuse signal. To quantify 
the levels of MYEF2-mCherry throughout the cell cycle, Myef2-mcherry NSCs were 
incubated with Hoechst 33342 and analysed by flow cytometry. Using Hoescht 33342 
determined cellular DNA content and ploidy, we observed that the levels of MYEF2-
mCherry were similar between G0/G1 (2N), S phase and G2/M (4N). The same was 
also observed for SOX2-mCherry (Fig 3.12). This indicates that there is a 
redistribution, rather than downregulation, of MYEF2 during mitosis. These findings 
suggest that although MYEF2 and SOX2 are interaction partners during interphase, 
the interaction with SOX2 during mitosis is broken. 
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Figure 3.12 | MYEF2-mCherry levels are consistent throughout the cell cycle 
Flow cytometry analysis of parental wild-type, Sox2-mCherry and Myef2-mCherry NSC 
lines incubated with Hoechst 33342. TO-PRO-III was used as a live-dead marker and 
parental line used for gating controls, n=2. (A) Flow cytometry plot of fluorescent intensity 
(mCherry vs Hoechst 33342) for each individual cell. (B) FlowJo V10 univariate cell cycle 
modelling to identify cellular ploidy. (C) Plot shows mCherry intensity of cells from the 
corresponding cell cycle population, with G1/G0 (2N) shown in red, S phase in yellow and 
G2/M (4N) in blue. 
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3.2.8 Interaction of MYEF2 and SOX2 in mitosis 
The earlier data revealed that SOX2 and MYEF2 interact in interphase under 
proliferative conditions (section 3.1.3). However, MYEF2 unlike SOX2 does not 
bookmark (section 3.2.7). We, therefore, next further explored the interaction between 
SOX2 and MYEF2 during mitosis. 
 
NSCs overexpressing a wild-type SOX2-GFP fusion protein (provided by Charles 
Williams) were incubated either with nocodazole, which disrupts microtubules and 
arrests cells in mitosis, or without nocodazole (Fig 3.13.A). From the anti-GFP 
nanobody immunoprecipitation of SOX2-GFP, we observed that MYEF2 co-
immunoprecipitated with SOX2 in the absence of nocodazole, but did not co-
immunoprecipitate in the nocodazole treated mitotically enriched sample (Fig 3.13.B). 
This confirms our earlier imaging data, that the interaction of SOX2 and MYEF2 is 
disrupted in mitosis. 
 
SOX2 undergoes mitotic phosphorylation251. We hypothesised that this 
phosphorylation may disrupt the SOX2/MYEF2 interaction. Mass spectrometry of 
NSCs identified several specific serine/threonine phosphorylation sites (Charles 
Williams, unpublished data). NSC lines with doxycycline inducible mutant SOX2-GFP 
were generated by piggyBac integration (cell lines by Charles Williams). Two variants 
of particular interested were the lines referenced to as 3A-SOX2, in which serine 
residues 251, 252 and 253 were mutated to alanine, and B5-MK-SOX2, in which all 
serine/threonine residues within amino acid stretch 240-280 were mutate to alanine. 
Each of these mutant NSC lines showed nuclear SOX2-GFP when induced with 
doxycycline (Fig 3.13.A), confirming the transgene was expressed and retained 
nuclear localisation at interphase (which is ~95%) of the population. IP of each of the 
two SOX2-GFP phosphorylation mutants failed to show the co-immunoprecipitation 
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of MYEF2 (Fig 3.13.B). This suggests that the phosphorylation of SOX2 impairs the 
binding to MYEF2. These data support a model in which mitotic kinases 
phosphorylate Sox2, and these phosphorylation sites are involved in the interaction 
of SOX2 with MYEF2. 
 
3.2.9 Mass spectrometry of MYEF2-HA in mouse NSCs  
To identify the interactome of MYEF2, mass spectrometry was performed on HA 
immunoprecipitated complexes from the Myef2-HA NSC line. HA immunoprecipitation 
and mass spectrometry in an untagged parental line was also carried out, providing a 
negative control. This was performed in three technical replicas by Alexander von 
Kriegsheim at the Edinburgh CRUK Centre Mass Spec core facility252.  
 
Proteins with an average intensity over untagged control ratio higher than 2, and a t-
test p value ≤ 0.05, were considered to be specific. From the filtered list, 75 candidate 
protein interactors of MYEF2 were identified (Appendix, table 9). One of these 
interactors was SOX2, further supporting previous observations. No other SOX 
factors were within the filtered list, though SOX8 was observed just after the cut off 
criteria with a ratio of 5.5 and p value of 0.058. This also supports our conclusions 
and data from the SICAP experiments. The filtered set of interactors were analysed 
in the gene ontology enrichment software, ClueGO232. Interactors of MYEF2 were 
over-represented in biological pathways associated with RNA processing, especially 
splicing (Fig 3.14, p value ≤0.05). This is consistent with the RNA binding (RRM) 
domains present within Myef2 and indicates that this protein is indeed enriched in 
RNA associated pathways. Further experiments are required to identify if MYEF2 
directly interacts with RNA and, if so, the biological relevance of interaction. However, 
these findings suggest it may have broad binding to the splicing machinery. 
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Figure 3.13 | Interaction of SOX2 and MYEF2 in mitosis 
(A) Representative live cell images of SOX2-GFP and mutant SOX2-GFP lines. Lines 
were treated with doxycycline for 48 hrs and nocodazole for 6 hrs. Parental wild-type line 
provided negative control. All GFP inducible lines were made by Charles Williams. Scale 
bar: 50 µm. (B) IP of SOX2-GFP and mutant SOX2-GFP lines with anti-GFP nanobody. 
Lines were treated with doxycycline for 48hrs and nocodazole for 6hrs. Parental wild-type 
line provided the negative control for the IP of SOX2-GFP. Phospho-histone H3 (Ser10) 
acts as a mitotic marker, indicating the mitotic enrichment mediated by nocodazole 
treatment. Immunoprecipitated SOX2-GFP was then probed for the co-
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Figure 3.14 | Mass spectrometry of MYEF2-HA in mouse NS cells 
Mass spectrometry data of MYEF2 interactors. MYEF2-HA was immunoprecipitated and 
complexes analysed by mass spectrometry. Identified interactors were then filtered based 
on the average intensity over control ratio and a t-test p value ≤ 0.05. n=3, technical 
replicas (performed by Edinburgh Cancer Centre, Mass Spec core). GO enrichment 
analysis, based on biological processes, was performed on the filtered data set  using the 
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3.3 Discussion 
SICAP coupled mass spectrometry was previously performed, and identified MYEF2 
as a candidate on-chromatin interactor of SOX2 in mouse GSCs. Co-
immunoprecipitation experiments confirmed that the interaction between MYEF2 and 
SOX2 occurs within normal mouse NSCs and mouse GSCs. The interaction between 
MYEF2 and SOX2 occurred both in the presence and absence of crosslinking, 
suggesting that MYEF2 interacts with SOX2 either directly or through a common 
complex. To conclusively conclude that MYEF2 and SOX2 directly interact, the 
interaction between purified proteins would need to be tested. The interaction of 
MYEF2 with other SOX factors (SOX3, SOX8 and SOX9) appears to rely on 
crosslinking, suggesting that the interaction observed in SICAP-MS maybe indirect, 
due to their co-localisation at certain chromatin regions or regulatory elements. 
Alternatively, the interaction of MYEF2 and other SOX factors, within the same protein 
complex, may be more transient or only occur in a small subsection of MYEF2 
containing complexes, escaping detection in the performed co-immunoprecipitation 
experiments. 
 
The preference of SOX2 binding compared to other SOX members is intriguing. This 
might be consistent with the anticipated role of SOX2 as a pioneer factor, that lies 
upstream of other members. We speculate that SOX2 and MYEF2 interactions may 
be important in recruitment of the other SOX members to key target loci. Preliminary 
SICAP-MS data on human glioma neural stems cells also identified MYEF2 as an on-
chromatin SOX2 interactor (Pooran Dewari, Pollard lab, unpublished data). 
Supporting our observations, independent studies have also previously identified 
MYEF2 as a SOX2 interactor. In ESCs overexpressing SOX2-Flag, which promotes 
ESC differentiation, the interaction between SOX2 and MYEF2 was observed253.  The 
interaction between SOX2 and MYEF2 was also enriched in medulloblastoma DAOY 
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cells overexpressing inducible SOX2 compared to uninduced cells254. Finally, MYEF2 
has been observed to co-immunoprecipitate with flag-SOX2 purified from the nuclear 
extract of NSCs255. From our data, and that of others, we show that MYEF2 is an 
interactor of SOX2 in NSCs. The interaction between MYEF2 and SOX2 appears to 
be ablated in mitosis. From live cell microscopy on Myef2-mCherry NSCs, MYEF2-
mCherry was not observed on the mitotic chromatin, though we cannot rule out that 
a small fraction of MYEF2 is not retained on specific sites during mitosis. This 
contrasts with SOX2, which we have identified as a clear binder to mitotic 
chromosomes and a potential bookmarking factor.  
 
Our most recent experiments suggest that it is the mitotic phosphorylation of SOX2 
that effects the interaction with MYEF2. Further experiments are required to confirm, 
that the mitotic phosphorylation of SOX2 disrupts the interaction of MYEF2 and SOX2, 
and the functional importance of this for continued self-renewal. The behaviour of 
MYEF2 does not mimic that of SOX2 when cells are exposed to differentiation cues. 
Upon exposure to BMP4/FGF2, BMP4 and serum, SOX2 levels drop, whilst levels of 
MYEF2 remain similar to those observed under proliferative conditions. MYEF2 is 
also still expressed within the nucleus of terminally differentiated cells. Thus, it is not 
as simple as MYEF2 simply being a key partner that is expressed only in the stem 
cells; it likely has broader roles in gene regulation in the differentiating progeny as 
well. 
 
Several tools to study MYEF2 have been generated in the experiments described in 
this chapter. Myef2-HA NSC line is useful for biochemical experiments and is likely to 
be used in future experiments such as ChIP-seq. When generating the myef2-
mCherry NSC line a high level of random integration was observed. Several clones 
which showed nuclear mCherry staining failed to show targeted knock-in of mCherry 
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by PCR genotyping. This occurred in 4 out of 7 clones screened. Some studies 
suggest that dsDNA templates undergo NHEJ in addition to HDR hence may 
contribute to the high level of random integration observed256. In future experiments 
ssODN templates will be used when possible. In addition to the high levels of random 
integration observed, 2 clones which showed targeted knock-in had large deletions 
within the untargeted Myef2 locus. The longer term plasmid based expression of Cas9 
and sgRNAs may contribute to this observation, as the recombinant Cas9 complex 
delivered for HA tagging is likely to reside within cells for a shorter duration.  
 
3.3.1 Concluding remarks 
To conclude, we observe that the RNA-binding protein MYEF2 interacts specifically 
with SOX2 in NSCs, and although co-localised with SOX3, SOX8 and SOX9 through 
SICAP-MS, the interaction with these other SOX members is likely to occur through 
co-localisation on similar chromatin regions. The interaction between MYEF2 and 
SOX2 is dynamic, with different subcellular localisation emerging in mitosis, possibly 
because of SOX2 phosphorylation. In the next chapter we used genetic ablation to 
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Chapter 4 The function of MYEF2 in glioblastoma 
 
4.1 Introduction  
In the previous chapter we validated the interaction of SOX2 and MYEF2 in both NSC 
and GSC lines, as well as the initial characterisation of MYEF2 expression in NSCs. 
This chapter focuses on our experiments to understand the function of MYEF2 in 
mouse GSCs through loss of function studies, with Myef2 knockout lines obtained 
through genetic ablation (CRISPR knock out). 
 
RNA-seq datasets from pan-cancer patient samples, indicate there is high levels of 
SOX2 transcripts within GBM and glioma patients (Fig 4.1.A, data from the TCGA41 
and analysis from the cBioPortal257,258). The high levels of SOX2 are observed within 
almost all GBM and glioma samples, supporting proposals that SOX2 is a core 
transcription factor in all molecular sub-types of GBM. MYEF2 transcripts levels are 
also high within almost all GBM and glioma samples, although levels are also high 
across a wider range of cancers types than SOX2 (Fig 4.1.B, data from the TCGA41 
and analysis from the cBioPortal257,258). A strong positive correlation between SOX2 
and MYEF2 transcript levels is also observed within GBM patient samples (Fig 4.2, 
data from TCGA259 and analysis from the cBioPortal257,258). This supports that MYEF2 
may be functioning alongside SOX2 in GBM, and if MYEF2 is therapeutically relevant, 
likely to be so in a wide range of GBM and glioma patients. 
 
To study the function of MYEF2 in glioblastoma, Myef2 mutant lines were generated 
using CRISPR/Cas9. The mouse Myef2 locus is composed of 17 coding exons, which 
encode for a protein of approximately 60 kDa predicated to have three RRM 
RNA/single stranded DNA binding domains (Fig 4.3). Several splice variants of Myef2 
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exist. All splice variants retain exons encoding the RRM domains and vary in the 
retention of exons 11 and 14. To knockout Myef2, guide RNAs which cut within the 
intronic regions either side of exon 2 were used. This strategy should affect all 
expressed splice variants of Myef2. Myef2 knockout lines were generated from a new 
mouse GBM model referred to as NPE (Ester Gangoso, unpublished data). This 
model contains mutation of Nf1, Pten and overexpression of human EGFRVIII, best 
modelling the mesenchymal sub-type of glioblastoma. It should be noted that this 
exact combination of mutations is rarely observed in human patients and this is a 
potential limitation of this model. In this chapter the model was generated through a 
multiplex transfection of multiple guide RNAs, against Nf1 and Pten, and piggyBac 
overexpression plasmids for EGFRVIII and GFP-Luciferase. Transfected cells were 
then sorted and transplanted into an NSG mouse. The subsequent tumour was then 
dissected, and single cell clones were then derived and screen for the relevant 
modifications. These clones are referred to as NPE-MX-TD (NF1-/-, PTEN -/-, 
EGFRVIII+ - multiplex - tumour derived) cells with a corresponding clonal ID (Cell line 
derivation was performed by Ester Gangoso, Pollard lab). This model was chosen for 
three main reasons: firstly, tumours form rapidly and reliably, making the model useful 
for in vivo studies; secondly, by avoiding the deletion of P53 it is more likely that 
genomic integrity is maintained and that knockout lines remain isogenic to the parental 
line, and thirdly this model corresponds to the mesenchymal subtype of GBM. 
 
Generated Myef2 knockout lines were subsequently used in a range of functional 
assays to assess the effect that the loss of MYEF2 has on the proliferation rate, colony 
formation potential, BMP sensitivity and tumour formation potential of GSC cells. 
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Figure 4.1 | Expression of SOX2 and MYEF2 in cancer 
(A) SOX2 RNA-seq data from pan-cancer TCGA data. GBM and glioma are highlighted 
in blue and in bold. (B) MYEF2 expression from RNA-seq analysis (TCGA data). GBM 
and glioma are highlighted in blue and in bold. Data for this panel was analysed by the 
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Figure 4.2 | Correlation of SOX2 and MYEF2 transcript levels in glioblastoma 
RNA-seq data comparing transcript levels of SOX2 and MYEF2 in GBM patient samples. 
Data for this panel is from a TGCA data set259 and analysed by cBioPortal257,258. 
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Figure 4.3 | Locus of Myef2 and predicted protein domains of MYEF2  
(A) Depiction of the locus of Myef2 within the mouse genome. Exons 1 to 17 are depicted 
as dark grey boxes.  (B) Depiction of the protein’s domains of MYEF2. Corresponding 
exons encoding the RRM domains are highlighted by dashed lines. Based on exon 
numbers from Myef2-209 transcript exons 2-6 contribute to RRM1, exons 6-9 contribute 
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4.2 Results 
4.2.1 CRISPR-Cas9 mediated generation of mouse GSC Myef2 knockout 
lines 
Two NPE-MX-TD clonal lines, clone 4 and clone 6, were used to derive MYEF2 
knockouts. Two different gRNAs were co-transfected into mouse GSC lines NPE-MX-
TD C4 and NPE-MX-TD-C6. The gRNAs were predicted to target intronic regions 
flanking exon 2, which encodes the majority of the proposed RNA binding domain 
RRM1, which is retained in all splice variants of myef2 (Fig 4.3). Single cells were 
then sorted into 96 well plates by FACS and ~120 clones for each line were picked 
and genotyped. As two gRNAs were used, the PCR genotyping strategy was 
designed to identify the deletion of a 403 bp segment, of which 209 bp corresponds 
to exon 2, of DNA between the gRNAs (Fig 4.4.B). Fragment sizes were based on the 
assumption that the Cas9: gRNA complex cuts 3 bp upstream of the PAM sequence. 
While this strategy may underestimate the number of targeted clones; for example, if 
larger deletions occur which also remove the sequences encoding the genotyping 
primers, it is simple, relatively fast and sufficient to screen targeted clones.  
 
From the isolated clones, 7 clones of the 125 clones picked from parental line NPE-
MX-TD C4 and 8 clones of the 129 clones picked from parental line NPE-MX-TD C6, 
were identified as knockouts based on PCR genotyping (Fig 4.4B). Clones positive 
for targeting by genotyping were then verified for the loss of MYEF2 protein by 
western blotting (Fig 4.4.C). Clones with the exception of two false positives, clone 47 
and clone 88, were identified to be Myef2 knockout lines. 
 
The expression of EGFRVIII is key to the tumour forming potential of the NPE line, 
with isogenic lines containing only the deletion of NF1 and PTEN (NP line) failing to 
form tumours. To ensure that the piggyBac integrated human EGFRVIII had not been 
silenced within individual Myef2 knockout clones, immunoblotting against phospho-
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tyrosine1068 EGFR was performed (Fig 4.4.C).  In response to ligand binding and 
dimerization, intracellular tyrosine phosphorylation occurs within EGFR. As EGFRVIII 
is truncated and constitutively active260, the total EGFRvIII protein expression is 
detected by the pY1068 antibody and can be identified from endogenous EGFR by 
its reduced size. All mutant lines retained the expression of EGFRVIII, though the 
levels varied. The MYEF2 knockout clones highlighted in red were used in the 
subsequent experiments and were selected so range of EGFRVIII levels were 
represented. 
 
4.2.2 Myef2 knockout GSCs retain NSC markers and differentiation 
potential  
Myef2 knockout mouse GSC lines can be maintained in vitro over several passages, 
with cells retaining the expression of neural stem cell markers BLBP, NESTIN and 
SOX2 (Fig 4.5.A). Based on GFAP (astrocytes) and TUJ1 (neurons) (Fig 4.5.B), we 
found that Myef2 knockout clonal lines retained the capacity to differentiate into 
astrocytes and neurons. From initial observations the in vitro astrocytic and neuronal 
differentiation capacity of Myef2 knockout lines was not dramatically different from the 
parental line. However, more experiments would be required to determine this, 
especially due to the low frequency of neuronal differentiation and the high 
heterogeneity of differentiation experiments. The low efficiency is likely due to a 
differentiation block imposed by the transforming mutations that the NPE line has 
been engineered with. Neither the parental line nor the Myef2 knockout lines 
differentiated to MBP positive oligodendrocytes.  
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Figure 4.4 | Generation of mouse GSC Myef2 knockout lines 
(A) Schematic of Myef2 locus. Two guide RNAs, depicted in yellow, were used to generate 
double strand breaks within the intronic regions flanking either side of exon 2. PCR 
genotyping primers were designed outside of the cut sites and are depicted as F1 and 
R1. (B) Representative genotyping of NPE-MX-TD C6 clones 26-42 with primers F1 and 
R1. Sizes of expected wild-type and knockout bands are highlighted. (C) Western blotting 
of clones identified as knockouts by genotyping. Lower band of pY1068 plot corresponds 
to hEGFRVIII, whilst the higher band to endogenous EGFR. Clones highlighted in red 
were used in subsequent experiments. Data for panel C was provided by Carla Blin. 
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Figure 4.5 | Myef2 knockout lines retain NSC marker expression and differentiate 
with low efficiency 
(A) Representative ICC images of parental NPE-MX-TD and Myef2 knockout lines stained 
for NSC markers BLBP, NESTIN and SOX2 (n=1). Scale bar:50 µm. (B) Representative 
ICC images of parental NPE-MX-TD and Myef2 knockout lines differentiated to the 
astrocytic lineage (above) or neuronal lineage (below). Cells were stained for GFAP 
(astrocytic marker) or Tuj1 (neuronal marker). Undifferentiated parental line provided 
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4.2.3 Investigating the proliferation rate of GSC Myef2 knockout lines  
The recovery of mutant Myef2 cell lines suggested that MYEF2 is not essential for NS 
cell self-renewal. This is in contrast to SOX2 knockout, which has previously been 
shown to be critical, and no knockout lines can be recovered81,261. We therefore 
characterised, more carefully, the proliferation rates of the MYEF2 knockout cells.  
 
Using thymidine analogue EdU incorporation assays, we directly compared the 
growth rates of parental lines to those of Myef2 knockout lines. Three different clones 
were tested for both of the independent parental NPE-MX clonal lines. EdU was 
incorporated into newly synthesised DNA of an asynchronous population during a 2-
hour pulse period. Cells were cultured in complete NSC media supplemented with 
EGF and FGF2. The percentage of cells with EdU incorporation observed in Myef2 
knockout clones 2 (KO2) and 50 (KO50) was very similar to that observed for the 
parental NPE-MX-TD C4 line, indicating these lines have a similar proliferation rate. 
However, one clone, the Myef2 knockout line KO99 had a more drastic reduction in 
percentage of EdU incorporation compared to the parental NPE-MX-TD C4 line, 
though unfortunately this was not statistically significant (p value of 0.3, nested t test)  
 
Myef2 knockout clone 33 (KO33) derived from the independent parental line NPE-
MX-TD C6 displayed a significant reduction in EdU incorporation compared to the 
parental line. Myef2 knockout clones 110 (KO110) and 119 (KO119) did not have a 
statistically significant reduction in EdU percentage with nested t test p values of 0.24 
and 0.11 respectively. Whilst not always statistically significant all Myef2 knockout 
clones showed a clear trend of reduction in EdU incorporation, with the fold reductions 
(based on mean values) varying from 1.02 to 1.6 (Fig 4.6). Whilst there is a high level 
of variability between knockout clones, the data indicates that the loss of Myef2 leads 
to a slight reduction in the proliferation rate. 
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Figure 4.6 | Investigating the proliferation rate of GSC Myef2 knockout lines 
Quantification of the percentage of cells with the integration of thymidine analogue EdU 
following a 2 hour pulse period. Cells are grown in complete NSC media supplemented 
with growth factors EGF and FGF2. Plots show mean percentage of EdU positive cells ± 
SD, with individual technical mean data points shown. For parental line NPE-MX-TD C4 
and corresponding knockout lines n=2 biological replicas, with a minimum of 2 technical 
replicas within each experiment. For parental line NPE-MX-TD C6 and corresponding 
knockout lines n=4 biological replicas, with a minimum of 2 technical replicas within each 
experiment. For statistical analysis Nested t tests were performed with each knockout 
being compared to the relevant parental line. One star represents a p value ≤ 0.05, two 















































Myef2 knock-out clones 
from parental NPE-MX-TD C4
Myef2 knock-out clones 















   
  96 
4.2.4 Colony formation potential of Myef2 knockout GSCs 
A more stringent test of self-renewal and proliferation capacity is to examine the 
capability of a single GSCs to produce colonies when plated at a low density. 500 
cells were seeded into 10 mm dishes in complete NSC maintenance media with EGF 
and FGF2. Colonies were allowed to form over 10-15 days and were the quantified. 
The number of colonies observed was highly variable between experiments, however 
there was a clear trend, within each experiment, in which NPE-MX-TD Myef2 
knockout GSCs form fewer colonies than the corresponding parental NPE-MX-TD 
(Fig 4.7. A). In addition to forming fewer colonies, the colonies of Myef2 knockout 
GCSs appeared to be smaller. In an attempt to represent and quantify this the Fiji 
plugin ColonyArea was used, which calculates the plate area occupied by the 
colonies, giving an indication of the size of the colonies, and the intensity, which 
indicates the number of cells within a colony. For parental NPE-MX-TD C4 and the 
corresponding Myef2 knockouts this emphases the differences when MYEF2 is lost 
while, for C6 the differences were similar to those observed by the colony number 
alone (Fig 4.7.B and C). To conclude, preliminary experiments suggest that the loss 
of MYEF2 causes GSCs to be less clonogenic. 
 
4.2.5 BMP4 sensitivity of Myef2 knockout GSCs 
In NSCs and GSCs, BMP4 can mediate the upregulation of astrocytic markers, such 
as GFAP, and cell cycle exit. The degree of response varies both between NSCs and 
GSCs. GSCs generally considered to be more resistant to the cytostatic signals of 
BMP4 than NSCs, and response level between each GSC line can vary 
dramatically262. In response to BMP4 signalling, a high percentage of NPE-MX-TD 
and Myef2 knockout NPE-MX-TD cells increase the expression of astrocytic marker 
GFAP (Fig 4.8). To assess the sensitivity of cells to the cytostatic response of BMP4 
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signalling, the degree of EdU incorporation in varying BMP4 concentrations was 
measured. Following a 2 hr pulse of EdU, we observed that, whilst not significant 
(Mann Whitney U test, p value <0.05), there is a general trend for Myef2 knockout 
cells to have a lower percentage of EdU incorporation relative to the corresponding 
parental NPE-MX-TD cells (Fig 4.8.A), though as previously observed there is some 
variability in degree of response between clones. This suggests that Myef2 knockout 
GSCs are more sensitive to BMP4, though EdU incorporation levels did not drop to 
those of normal NSCs. NPE-MX-TD C6 had a higher percentage of EdU positive cells 
relative to NPE-MX-TD C4, indicating NPE-MX-TD C6 is less responsive to the 
cytostatic signals of BMP4. This observation is in line with the higher levels of Bmpr1 
expressed in NPE-MX-TD C4 (Bmpr1 expression levels observed by qPCR, Kirsty 
Ferguson, Pollard lab). 
 
To ensure that slow cycling cells were also scored, a 24hr pulse with EdU was 
performed (Fig 4.8.B). Levels of EdU incorporation were lower in Myef2 knockouts 
compared to the corresponding parental line, though this trend was not statistically 
significant (Mann Whitney U test, p value <0.05). Parental NPE-MX-TD C6 had a 14% 
incorporation rate of EdU, while NPE-MX-TD C6 Myef2 knockouts a range of 3.5%, 
2.1% and 4.6%. NPE-MX-TD C4 had a 4.3% incorporation rate, while Myef2 
knockouts a 1%, 2.3% and 1.5% incorporation. NSCs had a 0.5% incorporation rate 
of EdU.  This data suggests that, the loss of MYEF2 increases the sensitivity of GSCs 
to the cytostatic signals of BMP, though further replicas are required to confirm this. 
   
  98 
 
Figure 4.7 | Colony formation potential of Myef2 knockout GSCs 
(A) Quantification of the number of colonies formed from the corresponding cell lines. 
Single cells were seeded and colonies that had formed after 10-15 days were stained with 
0.01% of methyl blue. Graph shows mean colony number from 2 replicas, with individual 
data points shown (orange= replica 1, blue= replica 2 data points). (B) and (C) show the 
% area that colonies occupy and the intensity, correspondingly, calculated using the fiji 
plugin ColonyArea233.  Graph shows mean from 2 replicas, with individual data points 
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Figure 4.8 | BMP4 sensitivity of Myef2 knockout GSCs 
(A) Quantity of proliferative cells in varying concentrations of EGF, FGF2 and BMP4. 
Graph shows percentage of EdU positive cells after a 2 hr pulse period in normal NS, 
parental NPE-MX-TD and corresponding Myef2 knockout cells treated for 3 days in 
varying concentrations (ng/ml) of growth factors EGF/FGF2 and differentiation promoting 
BMP4. Plot shows the mean percentage ± SD from 2 replicas. (B) Quantification of 
proliferating cells after treatment with BMP4. Normal NS, parental NPE-MX-TD and Myef2 
knockout cells were treated with BMP4 (10 ng/ml) for 3 days. Percentage of EdU after a 
24 hr pulse period was then calculated. Graph shows mean percentage of EdU positive 
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4.2.6 Re-entering the cell cycle from dormancy (G0)  
Previous studies have shown that GSCs are not terminally differentiated by BMP434 
and are capable of returning back into the cell cycle after BMP4 treatment262. Recent 
studies from Maria Angeles Marques in fact suggest NSCs treated with BMP4 enter 
a dormant (G0) state (unpublished observation), To assess if GSCs lacking MYEF2 
are in a deeper G0 state than cells with MYEF2, cells were treated with BMP4 for 3 
days, then re-added to NSC maintenance media supplemented with growth factors 
EGF/FGF2 for 10-15 days, till colonies formed (Figure 4.9). As expected, no colonies 
were observed from normal NSCs (non-cancerous). We observe that parental NPE-
MX-TD C4 GSCs forms few colonies and the corresponding Myef2 knockouts almost 
none (Fig 4.10.A). Parental NPE-MX-TD C6 GSCs form many more colonies when 
returning to proliferative conditions, whilst Myef2 knockouts derived from the NPE-
MX-TD C6 parental lines form very few colonies (Fig 4.10.B).  
 
As there are differences in the BMP sensitivity (4.2.5) and colony formation potential 
(4.2.4) of Myef2 knockout lines it is possible the differences observed in this assay 
arise from a combination of these factors, as opposed to differences in re-entry from 
dormancy. In an attempt to quantify this, the differences between BMP sensitivity (Fig 
4.8) and colony formation potential (Fig 4.7) of Myef2 knockout lines compared to the 
parental lines were calculated and combined. This gave rise to the expected ratio, the 
difference in colony number expected to be observed between parental and Myef2 
knockouts assuming no differences in the ability to re-enter cell cycle exists. Expected 
ratio differences of parental compared to Myef2 knockouts were then compared to the 
observed ratio differences (the differences in experimentally observed colonies 
numbers of Myef2 knockout compared to the parental line). These are presented in 
table 4.1 for C4 and table 4.2 for C6.  
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Table 6: Predicted and observed colony numbers for NPE-MX-TD C4 and 
corresponding Myef2 knockouts GSCs 
 
 
Table 7: Predicted and observed colony numbers for NPE-MX-TD C6 and 
corresponding Myef2 knockouts GSCs 
 
 
Generally, the observed reduction in the colony numbers of Myef2 knockout clones is 
higher than the expected ratio. This suggests that the loss of MYEF2 reduces the 
ability of GSCs to re-enter the cell cycle after BMP4 treatment. However, these data 
were highly variable. We can therefore not yet conclude that re-entry from dormancy 
requires MYEF2. Future experiments using increased replicates and/or rescue 
experimentations are required for this. Additionally, exploration of changes to the 
epigenetic landscape including the methylation and chromatin accessibility profile of 
cells, especially at genes associated with astrocytic differentiation (such as S100A6),  
Cell line Observed colony 
number (average) 
Expected ratio  
(relative to parental) 
Observed ratio  
(relative to parental) 
NPE-MX-TD C4 11 1 1 
KO2 1 1/8  1/11 
KO50 6 1/3 6/11 
KO99 1 1/33 1/11 
Cell line Observed colony 
number (average) 
Expected ratio 
(relative to parental) 
Observed ratio 
(relative to parental) 
NPE-MX-TD C6 37 1 1 
KO33 3 1/10 3/37 
KO110 2 1/8 2/37 
KO119 2 1/3 2/37 
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may provide alternative methods to indicate the extent of altered differentiation/G0 
depth vs de-differentiation/re-entry to the cell cycle38,86. 
 
4.2.7 Tumour formation potential of Myef2 knockout GSCs 
Parental NPE-MX-TD lines and corresponding NPE-MX-TD MYEF2 knockout lines 
were transplanted into the frontal cortex of adult male NOD scid gamma (NSG) mice. 
NPE-MX-TD lines, and corresponding Myef2 knockouts, constitutively express a 
randomly integrated GFP-luciferase construct, allowing for in-vivo imaging and 
identification of injected cells ex-vivo. Upon the development of symptoms, such as 
fitting, mice were culled and brains dissected to asses for the formation of tumours. 
All mice injected formed a tumour at the site of injection.  Tumours from parental lines 
and Myef2 knockout lines appeared to be similar in size and in the degree of infiltration 
(Fig 4.11.A and Fig 4.12.A). Survival curves indicate that Myef2 knockout lines have 
slower tumour growth than corresponding parental lines. The median survival time of 
parental NPE-MX-TD C4 was 13 days, whilst the median survival times of MYEF2 
knockout clones 2 and 50 were 21 and 23 days respectively. With parental NPE-MX-
TD C6 a median survival time of 15 days was observed, with median survival times 
of 17 and 18 days observed for Myef2 knockout clones 33 and 110 respectfully (Fig 
4.11.B and Fig 4.12.B). The observed differences between Myef2 knockout lines and 
the isogenic parental line are significant, suggesting that the loss of Myef2 slows the 
tumour formation rate of mouse glioma neural stem cells. 
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Figure 4.9 | Schematic of re-entry to the cell cycle from dormancy (G0) 
Schematic of the re-entry into the cell cycle assay performed in section 4.2.6 and figure 
4.10. Cells are treated for 3 days with 10 ng/ml BMP4 inducing the expression of astrocytic 
marker GFAP, changes in cellular morphology and a dormant state (G0). After 3 days, 
cells are returned to proliferative conditions (NSC maintenance media with growth 
factors).  
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Figure 4.10 | Exit from dormancy (G0) of mouse Myef2 knockout GSCs 
Cells were plated in BMP4 for 3 days to induce differentiation and exit from the cell cycle. 
Subsequently, cells were reintroduced to proliferative NSC conditions (NSC maintenance 
media supplemented with EGF/FGF2) and colonies were allowed to form. Colonies were 
then fixed, stained with 0.01% methyl blue and colony numbers quantified. Example 
images and colony quantification for (A) NPE-MX-TD C4 GSCs and corresponding 
knockouts and (B) NPE-MX-TD C6 GSCs and corresponding knockouts. Graph shows 
mean number of colonies ± SD from 3 replicas. 
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4.2.8 Rescue of Myef2 knockout GSCs  
To more robustly asses that previous observations from the derived knockout clonal 
lines are only due to the loss of MYEF2, and not additional unintentional difference 
between KO and parental GSCs, rescue lines were generated in knockout clones 
KO110 and KO119. A Myef2-HA-IRES-puromycin selection cassette under control of 
the TRE3G promoter (Fig 4.13.A) was randomly integrated into cells co-transfected 
with a constitutive TET-On-3G vector. Selection for transfected cells in doxycycline 
and puromycin was performed for 5 days. All control cells, treated with puromycin in 
the absence of doxycycline, died by day 3 of selection. Surviving cells were expanded 
and checked for the inducibility of HA. A very low percentage of HA positive cells was 
observed, approx. 3% for KO110 and 5% for KO119 (Fig 4.13.B). This was 
unexpected based on the selection. The cells were then plated in BMP4 in the 
presence or absence of doxycycline for 3 days, then subsequently retuned to growth 
factors in presence or absence of doxycycline and colonies allowed to form for 10 
days (as described in section 4.2.6). In all lines colonies formed at a similar rate in the 
presence and absence of doxycycline (Fig 4.13.C). Some colonies formed in Myef2 
knockouts in both presence and absence of doxycycline, but none of these stained 
positive for HA (data not shown). From these observations it was not possible to 
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Figure 4.11 | Tumour formation of Myef2 knockout lines derived from parental NPE-
MX-TD C4 line 
(A) Representative stereo microscope images of brains dissected from post-
transplantation symptomatic NSG mice. NPE-MX-TD C4 line and corresponding Myef2 
knockout lines are engineered to constitutively express GFP-luciferase, hence tumours 
are labelled with GFP. (B) Survival curves of NSG mice after transplantation with parental 
NPE-MX-TD C4 line (black), Myef2 knockout line clone 4 (KO4, orange) or Myef2 
knockout clone 50 (KO50, purple). P values were generated from the log-rank (Mantel-
Cox) statistical test. One star represents a p value ≤ 0.05, two stars a p value ≤0.01 and 
three stars a p value ≤0.001. 
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Figure 4.12 | Tumour formation of Myef2 knockout lines derived from parental NPE-
MX-TD C6 line 
(A) Representative stereo microscope images of brains dissected from post-
transplantation symptomatic NSG mice. NPE-MX-TD C6 line and corresponding Myef2 
knockout lines are engineered to constitutively express GFP-luciferase, hence tumours 
are labelled with GFP. (B) Survival curves of NSG mice after transplantation with parental 
NPE-MX-TD C6 line (black), Myef2 knockout line clone 33 (KO33, red) or Myef2 knockout 
clone 110 (KO110, blue). P values were generated from the log-rank (Mantel-Cox) 
statistical test. One star represents a p value ≤ 0.05, two stars a p value ≤0.01 and three 
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Figure 4.13 | Inconsistent Myef2 expression hampered attempted exogenous 
rescue of MYEF2 knockout GSCs 
(A) Depiction of the piggyBac integration plasmid used to exogenously express a single 
myef2 isoform. Plasmid was assembled using EMMA. (B) Representative ICC images of 
MYEF2 knockout lines KO110 and KO119 transfected with myef2 plasmid and selected 
for stable piggyBac integration with puromycin. Parental line was not transfected and 
provided a negative control. Scale bar: 50 µm. (C) Number of colonies observed after cells 
were treated with BMP4 for 3 days and subsequently returned to growth factors 
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4.3 Discussion 
From the generation of isogenic Myef2 knockout GSCs we were able to begin 
assessing the function of MYEF2 in glioblastoma. We observed that the loss of 
MYEF2: reduces the in vitro proliferation rate; reduces the colony formation potential 
and increases the BMP4 sensitivity of GSCs in vitro. In vivo tumour formation potential 
is reduced when MYEF2 is ablated in mouse GSCs. 
 
Quantification of EdU incorporation highlighted that, the loss of MYEF2 causes a 
minor reduction in the proliferation rate of GSCs. This observation was only significant 
(p value <0.05 nested t test) for one clone, with all clones showing a mean decrease 
in EdU percentages. The degree of reduction in proliferation varied between each 
individual knockout clone, which may either reflect inherent cell variability acquired 
throughout cell culture or, more likely, the acquisition of different CRISPR/Cas9 off-
target effects when generating the Myef2 knockout lines. The observed reduction in 
proliferation was generally a relatively modest reduction, while the loss of SOX2 is 
predicted to mediate a greater effect on the proliferation rate, though the effect of 
SOX2 loss on the NPE model has not been directly tested. This indicates that either 
MYEF2 is not essential to all functions of SOX2 or there is functional redundancy 
between MYEF2 and another unknown protein.  
 
Preliminary experiments indicated that the colony formation potential of Myef2 
knockout lines is reduced. In addition to reduced colony numbers, the colony sizes of 
Myef2 knockout cells were also generally smaller, which is likely to reflect the reduced 
proliferation rates observed upon the loss of MYEF2. Unfortunately, the differences 
in clonogenic potential observed between parental and Myef2 knockout were not 
significant (Mann U test p<,0.05). The clonogenic assay used was highly variable 
between experiments and failed to form colonies during attempts to obtain further 
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replicas. In order to conclusively state that the loss of MYEF2 causes GSCs to form 
fewer colonies, it will be necessary to further optimise the clonogenic assay most likely 
by varying: the plating density; tissue culture plastic, and pre-coating treatment of 
tissue culture plastic. 
 
GSCs are often less sensitive than normal NSCs to the cytostatic effects of BMP4. In 
the absence of MYEF2 we observe fewer EdU positive cells when cells are treated 
with BMP4, indicating that MYEF2 contributes to cytostatic resistance. Fold 
differences of between 2-fold and 7-fold were observed when 10ng/ml BMP4 were 
used (Fig 4.8).  In general, NPE-MX-TD C4 and the corresponding Myef2 knockouts 
lines were more sensitive to the cytostatic cues of BMP4 than NPE-MX-TD C6 and 
the derived knockouts. This is likely to reflect the higher initial expression levels of 
Bmpr1 that are found in NPE-MX-TD C4.  The increased sensitivity of Myef2 knockout 
lines, may make GSCs lacking MYEF2 more sensitive to differentiation therapy, 
though the levels of cells which had exited the cell cycle did not drop to those observed 
in normal NSCs (Fig 4.8).  
 
The loss of MYEF2 significantly increased the survival times of transplanted mice. 
This slower rate of tumour formation was observed for all Myef2 knockout clones 
tested. The degree to which survival is affected by MYEF2 loss does not appear to 
correlate with some of the in vitro observations. Myef2 knockout clone KO50 had the 
greatest increase in median survival time compared to the parental line NPE-MX-TD 
C4, whilst from the in vitro data this clone had the most modest reductions in 
proliferation, colony formation potential and BMP sensitivity. Myef2 knockout clone 
KO33 on the other hand had some of the strongest in vitro differences compared to 
the parental line but showed the smallest increase in median survival times. The 
observed differences between in vitro and in vivo responses, highlight some of the 
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limitations of in vitro studies, which fail to investigate many components involved in 
tumour formation capacity including immune evasion, angiogenesis, invasiveness, 
the microenvironment and the brain extracellular matrix (ECM). Histology and 
immunohistochemistry (IHC) on control and Myef2 knockout tumours will provide 
insight into several of these factors, with staining of blood vessels, e.g. through CD31 
staining, indicating angiogenesis and staining for GFP, which marks the injected 
cancer cells, highlighting the degree of infiltration and invasion. As NSG mice, which 
only have functional neutrophils and monocytes and lack functional macrophages, 
dendritic cells, mature B/T cells, natural killer (NK) cells, were used for the in vivo 
tumour formation capacity experiments described in this thesis, investigations into the 
effect of MYEF2 loss on immune evasion will be limited. However, as the NPE-MX-
TD model is capable of forming tumours within the immune competent C57BL/6J 
strain, additional orthotopic transplantations experiments would enable for better 
investigation into the potential effects of MYEF2 loss on immune evasion and the 
tumour microenvironment. Overall in the absence of MYEF2, GSCs form tumours at 
a modestly slower rate. 
 
To support that the observations occurring are purely from the loss of MYEF2, and no 
other off-target effect of CRISPR/Cas9, we attempted rescue experiments to return 
MYEF2 expression to the knockout lines. Puromycin selection only gave a small 
population of cells that could induce immunocytochemistry observable MYEF2-HA 
protein – perhaps because Myef2 overexpression cannot be tolerated. As expected, 
based on the low percentage of the inducible population, no clear differences in colony 
numbers were observed between induced and uninduced samples when cells were 
tested for their ability to exit from the dormant state. It is necessary to repeat this 
experiment with a purer population in which more cells are inducible. To achieve this, 
it may be best to produce a new line in which fluorophore, so can sort without keeping 
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levels on for a long time in case of dosage issues. Other issues including our use of 
non-physiological levels and the use of only one isoform. These may also contribute 
to the negative result of this preliminary experiment.  
 
4.3.1 Concluding remarks 
To conclude, whilst not always statistically significant, all data indicates that the loss 
of MYEF2 is unfavourable for GSCs. This is in line with the high levels observed within 
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Chapter 5 Tuneable degradation of transcription 
factors using SMASh 
5.1 Introduction 
By engineering a degron onto a protein of interest (POI), the levels of the engineered 
protein can be controlled post-translationally. In this chapter I focus on of the drug 
tuneable SMASh230 degron (Figure 1.6) 
 
Whilst many different experimental degrons have been reported, the SMASh degron 
has many advantages. Firstly, self-cleavage of SMASh from the C-terminal of the POI 
occurs in the non-drug treated state, thereby leaving the target protein minimally 
modified with only 8 residual amino acids (PGDEMEEC). This is unlike other degrons, 
such as the auxin system, which require the permanent addition of large tags to the 
POI, which can often interfere with protein function.  Secondly, the HCV NS3/4A 
inhibitor drugs, which inhibit the self-cleavage of the SMASh and hence mediate 
degradation of the POI, are FDA approved drugs which can be used in vivo studies. 
This is a major advantage when transitioning to in vivo systems as dosing and toxicity 
issues have already been studied. Recent studies have shown that, through the 
introduction of multiple mutations to the NS3 protease, variable sensitivity to different 
NS3 protease inhibitors can be generated263. These NS3 protease variants can be 
used to generate SMASh tags inhibited by different drugs, highlighting the potential 
to specifically target multiple proteins within the same population by using different 
inhibitors. Thirdly, only one engineering event is required when using the SMASh 
degron. Other systems are often bipartite and require significant optimisation of the 
levels. Due to these advantages, in addition to those generally achieved by degron 
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control, we were highly interested in assessing the control achieved by the SMASh 
degron.  
 
Using Sox2 I assessed the suitability of SMASh as a degron in mouse NSCs. SOX2 
is a key transcription factor in GBM and we have established methods to knock-in 
small and large tags to this locus 81,185, making Sox2 an obvious choice for this proof 
of principle study. 
 
We tested the ability of SMASh to control both transgenic and endogenous SOX2 
protein levels in vitro. Finally, to further understand the biological effect of endogenous 
SOX2 loss, in NSCs and GSCs, bi-allelic knock-in of the SMASh tag to Sox2 locus is 
required. Hence, I will describe a strategy which should enrich for the selection of cells 
with bi-allelic SMASh knock-in. 
 
5.2 Results  
5.2.1 SMASh control of a SOX2-mCherry transgene confirms 
controllable protein degradation in mouse neural stem cells 
We first generated two new plasmids containing either a doxycycline inducible Sox2-
mCherry-SMASh transgene or a control doxycycline inducible Sox2-mCherry 
transgene. A SOX2-fluorophore fusion protein was chosen in order to allow for more 
quantitative results, such as data obtained through flow cytometry. These plasmids 
were used to generate a stable transgenic Sox2-mCherry-SMASh mouse NSC line 
(termed, NSC-iS2C-SM) and a stable transgenic Sox2-mCherry mouse NSC control 
line (termed, NSC-iS2C). The addition of NS3/4A protease inhibitor asunaprevir 
(ASV) to these two lines, when induced to express the transgene, lead to the absence 
of SOX2-mCherry within the NSC-iS2C-SM line, but not within the control NSC-iS2C 
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line (Fig 5.1.A). This validated that SMASh is capable of controlling transgenic SOX2-
mCherry within mouse NSCs. 
 
Next, to determine the concentrations of ASV which give a tuneable range of SOX2 
degradation, NSC-iS2C-SM and NSC-iS2C lines were induced with doxycycline, and 
simultaneously treated with ASV concentrations varying from 0 µM to 1 µM (Fig 5.1.B 
and Fig 5.1.C). From western blotting, the addition of 1 nM ASV caused levels of 
SOX2-mCherry to drop and, at 1 µM of ASV SOX2-mCherry appears to be absent 
from the NSC-iS2C-SM line (Fig 5.1.B). It should also be noted that, only a very faint 
band was observed at 100 kDa within the NSC-iS2C-SM line in the absence of ASV. 
This is the predicted size of non-cleaved SOX2-mCherry-SMASh fusion protein, 
highlighting the efficient self-cleavage of SMASh from SOX2-mCherry in the absence 
of ASV. 
 
To obtain more quantitative results flow cytometry was performed (Fig 5.1.C). Once 
again, the tuneable range appears to be between 1 nM and 1 µM of ASV, with a drop 
in protein levels of 6% and 89% respectively, being observed in the NSC-iS2C-SM 
line, when normalising to the induced line without ASV. 1 µM and 10 µM of ASV 
caused a drop of 87.4% and 89% in SOX2-mCherry protein levels within the NSC-
iS2C-SM line, though levels were not reduced to those observed under uninduced 
conditions. This highlights the presence of residual protein not observed by western 
blotting (Fig 5.1.C). Whilst 10 µM of ASV gave the largest drop in SOX2-mCherry from 
the NSC-iS2C-SM line, toxicity was indicated by a 57.4% reduction of SOX2-mCherry 
in the control NSC-iS2C line. This toxicity of ASV at 10 µM, was further validated by 
growth rate analysis in unmodified mouse NSC and GSC lines (Fig 5.2). No alteration 
in growth rates were observed in either NSCs nor GSCs at concentrations of ASV up 
to 1 µM, while a drop in proliferation rate was seen at 10 µM of ASV (Fig 5.2). An 
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optimal ASV concentration of 1 µM was therefore selected for subsequence 
experiments. 
 
5.2.2 Endogenous knock-in of mCherry SMASh to the Sox2 locus 
The previous experiments were carried out using SOX2-mCherry overexpression, 
and therefore represent an excessive amount of SOX2. To confirm the SMASh tag is 
effective for endogenous genes, a SOX2-linker-mCherry-SMASh fusion protein was 
generated by CRISPR/Cas9 mediated knock-in to the endogenous Sox2 locus in 
mouse NSCs (Fig 5.3.A). Following transfection of NSCs with the targeting cassette 
and Cas9/crRNA/tracrRNA complex (RNP), mCherry positive cells were FACS sorted 
from a 0.05% positive population. 17/23 clones stained positive for nuclear mCherry 
and showed cassette integration by PCR (data not shown). 3/3 of these clones were 
positive for correct targeting by genotyping (Fig 5.3.B). All clones screened had wild-
type band by PCR, indicating all were heterozygous knock-ins.   
 
As expected, the addition of 1 µM of ASV, for 48 hrs, lead to a reduction of SOX2-
mCherry protein from the knock-in lines. From high exposure ICC images, residual 
SOX2-mCherry can be observed. However, the residual protein does not appear to 
be exclusively nuclear (Fig 5.3.C). Residual SOX2-mCherry protein, in addition to the 
larger non-cleaved SOX2-mCherry-SMASh fusion protein, can also be observed after 
48 hrs of ASV treatment by western blotting (Fig 5.3.D). In the absence of ASV no un-
cleaved SOX2-mCherry-SMASh fusion protein is observed indicating efficient self-
cleavage of SMASh from SOX2 (Fig 5.3.D). 
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Figure 5.1 | SMASh controls transgenic SOX2-mCherry protein levels 
(A) Representative live images 48 hrs after doxycycline (1 µg/ml) mediated transgene 
induction and 1 µM ASV treatment. ASV treatment was started on day 0. n=3. Scale bar: 
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uninduced control, were treated with 1µg/ml of doxycycline and ASV (0, 0.1, 1, 10, 100, 
1000 and 10000 nM) for 48hrs prior to collection. All samples contained 0.3% DMSO. 
n=1. (C) Flow cytometry for mCherry in samples, with the exception of uninduced control, 
treated with 1 µg/ml of doxycycline and ASV (0, 0.1, 1, 10, 100, 1000 and 10000 nM) for 
48hrs prior to collection. All samples contained 0.3% DMSO. Data from each line is 
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Figure 5.2 | Confluency curves of mouse NSCs and GSCs in ASV to asses toxicity  
Confluency curves of mouse (A) NSCs and (B) GSCs treated with 0 µM (black) ,1 µM 
(orange) or 10 µM (green) of ASV in 0.3% DMSO. Plots show mean percentage 
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Figure 5.3 | Endogenous knock-in of mCherry-SMASh to the Sox2 locus 
(A) Schematic of targeting vector (repair template) and targeted Sox2 locus. CRISPR 
sgRNA, which cuts in the 3’UTR near the stop codon, is depicted by a yellow triangle. 
Using 500 bp homology arms, Sox2-mCherry-SMASh fusion protein sequence was 
generated. Grey lines represent flexible peptide linkers. PCR genotyping primers were 
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of 3 clones with primers F1 and R1. Sizes of expected wild-type and knock-in bands are 
highlighted. (C) ICC in wild-type parental line and a heterozygous Sox2-mCherry-SMASh 
line (+/s). Sox2-mCherry-SMASh line was treated for 48 hrs with DMSO or 1 µM of ASV 
(n=3). Scale bar: 25 µm. (D) Western blotting in wild-type parental and Sox2-mCherry-
SMASh lines. Cells were treated with either DMSO or 1 µM ASV for 48 hrs. (n=3) 
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5.2.3 Rate of SOX2-mCherry control by SMASh  
In the endogenous knock-in line unexposed to ASV there is an accumulation of SOX2-
mCherry which has been separated from the self-cleaving SMASh degron. This differs 
from section 5.2.1 where ASV was added simultaneously to doxycycline, hence the 
SMASh tag should not self-cleave, and SOX2-mCherry-SMASh will be degraded as 
it is generated. 
 
Hence, to determine the optimal duration of ASV treatment to induce the clearance of 
SOX2-mCherry a time course was performed using the knock-in reporter/degron line. 
By ICC a significant drop in SOX2-mCherry was observed after 16 hrs of ASV 
treatment. The additional reductions in protein levels occurring after 16 hrs appear 
comparatively minor by ICC, though after 48 hrs of ASV treatment the residual SOX2-
mCherry present is no longer exclusively nuclear (Fig 5.4.A). The localisation of 
residual SOX2-mCherry suggests it may not be functional, though further studies are 
required to determine this. By flow cytometry a 18% drop in SOX2-mCherry levels can 
be observed 6 hrs after initial ASV treatment. At 16 hrs of ASV treatment a drop of 
57.5% is seen and this increases to a maximal drop of 79% by 48 hrs of ASV treatment 
(Fig 5.4.B).  This time span required to see a drop in SOX2-mCherry, under SMASh 
control, needs to be considered when making future observations on the phenotypical 
effects caused by the loss of SOX2.   
 
After self-cleavage of the SMASh tag, the resulting SOX2-mCherry is no longer under 
SMASh control, and hence should not be affected by ASV addition. The loss of this 
protein is now dependant on its half-life. Assuming that, when adding ASV the rate of 
degradation of newly formed SMASh controlled protein is constant, the half-life of 
SOX2-mCherry in mouse NSCs is estimated to be around 14 hrs (Fig 5.4.B). This 
   
  123 
highlights how the SMASh tag can be used to estimate protein half-lives without the 
use of traditional protein synthesis inhibitors such as cycloheximide (CHX). 
 
5.2.4 Rapid post-translational reversibility of SMASh 
Control mediated by the SMASh tag is reversible, with the removal of ASV allowing 
for the re-accumulation of SOX2-mCherry. To determine the rate at which SOX2-
mCherry is re-established, cells were treated with 1 µM of ASV for 48 hr then ASV 
was washed out. By ICC, the return of nuclear protein can be observed 2hrs after 
ASV removal, with protein levels similar to pre-ASV treatment being observed 8hrs 
after ASV removal (Fig 5.5.A). This rapid return of protein fits with the post-
translational control that the SMASh degron offers.  Western blotting confirmed the 
reappearance of SOX2-mCherry 2 hrs after ASV removal. From ImageJ 
quantification, and normalisation to DMSO treatment, it can be estimated that 15 hrs 
after ASV removal SOX2-mCherry levels returned to 50% the amount to prior ASV 
treatment. It will be necessary to perform a longer time course to determine when 
SOX2-mCherry levels return to pre-ASV treatment levels as, 24 hrs after ASV removal 
SOX2-mCherry levels were only 63.8% of those observed in DMSO only treatment 
(Fig 5.5.B). This data demonstrates the reversible nature of SMASh, with exact 
timings likely to vary between proteins. 
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Figure 5.4 | Rate of SOX2-mCherry control by SMASh 
(A) ICC of Sox2-mCherry and Sox2-mCherry-SMASh endogenous knock-in lines. Cells 
were treated with 1 µM of ASV for varying time points (0,2,6,16,24,48 and 72 hrs). 
Representative images are shown (n=3). Scale bar: 50 µm. (B) Flow cytometry of Sox2-
mCherry and Sox2-mCherry-SMASh lines. Cells were treated with 1 µM of ASV for 
varying time points (0, 2, 6, 16, 24, 48 and 72 hrs). Wild-type parental line was used to 
set gates. Fluorescent mean intensity was normalised to 0hr time point. Plot shows mean 
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5.2.5 A strategy to enrich for the homozygous knock-in of SMASh   
Following the endogenous knock-in of mCherry-SMASh to the sox2 locus, we did not 
obtain any homozygous clonal lines. To enrich for the selection of cells with bi-allelic 
engineering, an alternative strategy was designed using two independent targeting 
vectors (Fig 5.6.A). Whilst a fluorophore has obvious advantages, the addition of a 
large tag to SOX2 maybe unfavourable. Instead of making a SOX2-mCherry fusion 
protein the mCherry was replaced with the small epitope tag HA. Secondly, the 
vectors contain fluorescent proteins mCherry or BFP, co-expressed from sox2 via a 
P2A “self-cleaving” peptide. Thus, the two final vectors that were constructed were: 
HA-SMASh-P2A-mCherry or HA-SMASh-P2A-BFP with homology arms directed to 
the C-terminal of SOX2. This would enable us to identify and sort red and blue double 
positive cells but have both with the same C-terminal HA fusion tag. This strategy 
might avoid the need to pick and screen clonal lines, as we would be confident 
working with the population. 
 
From a preliminary multiplex transfection experiment, dual positive cells could be 
observed by FACS, albeit it at low efficiency (25 double positives from 1353709 
corresponding to 0.002% of the live population). There appears to be a higher rate of 
integration of the mCherry targeting cassette (0.06%) over the BFP cassette (0.007%) 
within the multiplex sample (Fig 5.6.B). Similar integration efficiencies, 0.04% for 
mCherry and 0.01% for BFP, were observed by FACS from single cassette 
transfections (data not shown). Subsequent ICC (Fig 5.6.C) and genotyping (Fig 
5.6.D) indicate correct targeting of the single colours; however, the sorted population 
is not 100% targeted (Fig 5.6.C). Unfortunately, the dual positive cells did not survive 
and expand, and could not be further characterised. Future studies to obtain bi-allelic 
knock-ins will be performed using larger numbers of starting cells. 
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Figure 5.5 | Rapid post-translational reversibility of SMASh 
(A) Representative ICC of Sox2-mCherry-SMASh knock-in lines. Cells were treated with 
1 uM of ASV for 48 hrs. ASV was washed out and samples collected at varying points (0, 
2, 4, 6, 8 and 24 hrs) post-ASV removal. Scale bar :50 µm. n=3 (B) Representative 
Western blotting. Sox2-mCherry-SMASh lines were treated with 1 uM ASV for 48 hrs. 
ASV was washed out and samples collected at varying time points (0, 2, 4, 6, 8 and 24 
hrs) post ASV removal, n=3. (C) ImageJ analysis of SOX2-mCherry protein levels from 
western blotting. SOX2-mCherry-SMASh fusion was excluded from analysis. Data is 
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Figure 5.6 | Bi-allelic knock-in of SMASh 
(A) Schematic of targeting vectors (repair template) and targeted Sox2 locus. CRISPR 
sgRNA is depicted by a yellow triangle. PCR genotyping primers were designed outside 
of the homology arms and are depicted as F1 and R1. Vector was designed by Katrina 
McCarten and made by Rachel White. (B) FACS of mouse NSCs transfected using both 
targeting vectors. Non-transfected parental line was used to set gates. (C) ICC of BFP 
positive and mCherry positive sorted cells. Nuclear HA staining indicates correct targeting. 
(D) Genotyping from the bulk population of BFP positive and mCherry positive cells. 
Genotyping primers F1 and R1 were used. Sizes of expected wild-type and knock-in 
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5.3 Discussion 
SMASh is a relatively recently reported degron, with several advantages over more 
widely used degrons, such as AID. At the time of this study, no one had yet reported 
on the use of SMASh for neural stem cells or the transcription factor, Sox2. From our 
experimental data, we observed for the first time, that SMASh functions for both 
transgenes and knock-in reporters within mouse NSCs. Specifically, SMASh enables 
post-translation control of SOX2, with endogenously SMASh tagged SOX2 retaining 
its nuclear localisation even with the residual amino acids left by the self-cleaving tag. 
In agreement with our findings, a newly published study found SMASh be an effective 
degron for SOX2 in hPSCs and for FOXG1 in hPSC derived NPCs264. 
 
The self-cleavage of SMASh from the protein of interest leaves the protein minimally 
modified and hence, loss of the protein of interest is dependent on its half-life. While 
the kinetics of the SMASh degron are slower than some other degrons, we observed 
that the rate is still suitable for most studies. This feature also enables the SMASh 
system to be used to study the protein’s half-life, without the need for global protein 
synthesis inhibitors or complicated pulse-chase SILAC experiments. From our studies 
we estimated the half-life of SOX2-mCherry to be approximately 14 hrs. This 
estimation is longer than 5-6 hr SOX2 half-life predicted by the use of the protein 
synthesis inhibitor, cycloheximide 145,146.  From SNAP-tag® and Halo-tag® SOX2 
fusion proteins the half-life of SOX2 was estimated to be around 9 hrs in mouse 
ESCs265. This estimate is closer to the one we observe. The addition of the 
fluorophore mCherry may alter the degradation of SOX2 or using the SMASh system 
may give an overestimation of protein half-life.  
 
In order to use SMASh to investigate the phenotypic effects of SOX2 loss, it will be 
necessary to derive a line with bi-allelic knock-in of SMASh. By using tagging 
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strategies which include P2A-conjugated fluorophores, we observed that the knock-
in efficiency to the Sox2 locus is low (~ 0.05% for vectors with mCherry and 0.01% 
for vectors with BFP). This is not unusual, with similar low efficiency rates inferred by 
the use of antibiotic selection cassettes to obtain knock-in lines264,266, with dual 
antibiotic selection methods further enriching for  bi-allelic knock-ins264. To obtain bi-
allelic knock-in using our vectors either a large sample must be sorted or, as an 
alternative to multiplex transfection, transfection with each vector can be performed 
sequentially, enriching for targeted cells after each transfection by FACS. Either way, 
even from the efficiencies observed it should be possible to obtain bi-allelic knock-ins. 
Assessing the feasibility of this approach is also important for future studies with 
heterogenous human GBM patient lines (www.gcgr.org.uk), where the generation of 
clonal populations of engineered cells should be avoided. 
 
The translation of SMASh mediated control from in vitro to in vivo systems will be 
highly valuable but has been beyond the scope of this current thesis. Using current 
mouse GBM models (Ester Gangoso, unpublished) our lab has established protocols 
for tumour formation and monitoring; hence it should be feasible to allow a tumour to 
form and then look at the effect of knocking down the protein of interest. The observed 
in vitro concentration of ASV required to get maximal knock down of SOX2-mCherry 
is 1 µM, though further studies using between 100 nM and 1 µM of ASV should be 
performed to see if a lower dose will still give maximal knock down. The 
concentrations of ASV required in vitro are in line with those often observed in the 
liver of mice treated with ASV 267,268 and one study has shown the reduction of the 
protein BRM under SMASh control within a subcutaneous tumour when orally 
administering ASV269. A major potential limitation to using SMASh for in vivo studies 
is the inability of the NS3 inhibitors, including ASV270, to cross the blood brain barrier 
(BBB). It remains to be seen if this will be an issue for future studies as our mouse 
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GBM models create tumours which are thought to have a leaky BBB in the tumour 
bulk.  
 
Similar to previous reports264,269 we do not observe a complete loss of SOX2 when 
inducing degradation by ASV addition. It is unclear if this residual protein is still 
functional as it is composed of both SMASh fusion and non-fusion fractions and, more 
importantly, is not exclusively nuclear. Further exploration is required to determine if 
the residual SOX2 observed after ASV treatment is sufficient for normal cellular 
function. Due to the inability to completely remove all protein, the SMASh system is 
unlikely to replace knockout studies, but is a technology to supplement them. In fact, 
whilst the inability to ablate all of SOX2 initially appears like a negative feature of 
SMASh, the situation is much more likely to mimic acute knockdowns of proteins 
observed by therapeutic drugs. This, combined with the easy tuneability of protein 
levels achieved by SMASh, is particularly useful when assessing proteins for their 
therapeutic potential.  
 
5.3.1 Concluding remarks 
In summary, we demonstrate that the SMASh tag is an efficient degron offering easy 
tuneable control of SOX2 levels in neural stem cells. Future studies will soon be able 
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Chapter 6 General discussion 
 
In this thesis we aimed to understand the biological functions of the understudied 
SOX2 interacting protein, MYEF2. Additionally, we sought to explore the efficiency of 
the SMASh tag degron at degrading SOX2 in NSCs. Below, I will summarise the key 
observations and future directions of this investigation. 
 
6.1 The function of MYEF2 in NSCs and glioblastoma 
6.1.1 MYEF2 is SOX2 interactor, but does it interact with other SOX 
factors? 
Work from this thesis, the Pollard laboratory and others271,272 strongly support that 
MYEF2 is an interactor of SOX2 within NSCs and GSCs. In line with this we observed 
that global MYEF2 expression is high in the brain, suggesting a functional role which 
was subsequently studied. MYEF2 protein was also observed to be particularly high 
with the testis of adult mice. Recent studies have indicated that whilst, SOX3 is 
classically associated with spermatogonia stem cells (SSCs)103, a SOX2 expressing 
population of SSCs also resides in the testis112. It would be interesting to investigate 
if MYEF2 is a protein interactor of SOX2 or SOX3 within SSCs. Lower levels of MYEF2 
were also seen in the intestine, liver and heart. Within the intestine and liver, SOX9273 
is the main SOX factor predominantly associated with adult stem cells or progenitors 
cells. It would be extremely interesting to investigate, though RNA-FISH and IHC (if a 
good antibody is identified), if MYEF2 co-localises within the SOX expressing stem 
cell populations of multiple tissues and, through western blotting, if MYEF2 interacts 
with the SOX factors predominantly associated with these tissues. This will indicate if  
MYEF2 is involved in a global mechanism with varying SOX proteins or if the function 
is specific only to SOX2. 
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6.1.2 The biological function of MYEF2 
One of the major finding of this thesis was the effect that the loss of MYEF2 had on 
GSCs. Loss of MYEF2 generally reduced the competitiveness of GSCs, with reduced 
proliferation rates, reduced colony formation potential, increased BMP sensitivity and 
most dramatically increased survival rates of transplanted mice being observed. This 
was perhaps not unsurprising due to its interaction with SOX2 and high levels of 
expression within NSCs and GSCs but adds strong support that MYEF2 is playing a 
functional role in GBM. The phenotype of Myef2 knockout GSCs was mild compare 
to that expected for GSCs lacking SOX2, suggesting that MYEF2 is not essential for 
the function of SOX2 but aids it to work efficiently. Currently all observations on the 
function of MYEF2 are within mice and a MES specific CSC model. It will be both 
interesting and necessary, to determine if the phenotypic observations observed from 
MYEF2 loss are maintained within multiple CSCs, modelling a range of transcriptional 
subtypes, and within human GBM samples, hence providing information as to if 
MYEF2 is relevant to clinical cases of GBM. It should also be noted that within this 
thesis emphasis was placed on studying the interaction of SOX2 and MYEF2. 
However, MYEF2 has previously been shown to interact with RUNX1 within mouse 
erythroleukemia cells135. RUNX1 is overexpressed in the MES subtype of GBM and 
is thought to contribute to the MES subtype and increased invasion capacity, via the 
TGFß pathway274. The potential links of MYEF2 and RUNX1 within GBM is still to be 
explored, with this link highlighting the requirement for more extensive 
characterisation of Myef2 knockout tumours as previously discussed. 
 
The next major step for this work is to identify the molecular mechanisms of MYEF2 
and determine how they link with SOX2. Based on the structure and functional 
domains of MYEF2, we propose MYEF2 is likely to function as an RNA binding 
protein. Supporting this several studies have identified that MYEF2 binds to a range 
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of RNAs including mRNAs275,276  and the long noncoding RNA (lncRNA) XIST134,277. 
Based on current data we tentatively propose two potential mechanisms for MYEF2.  
The first hypothesis is that MYEF2 functions through lncRNA. lncRNA (>200nt) are 
generally transcribed by RNAPII, evolve more rapidly than protein encoding gene and 
tend to have restricted expression in specific tissues.  
 
The mechanism of action of many lncRNAs is still elusive. However, several have 
been found to mediate transcriptional regulation through recruitment of chromatin 
modifying complexes278–280, transcription factors281, preventing transcriptional factor 
access282 and potentially through chromatin organisation283–285. Through interacting 
with lncRNAs, we propose that MYEF2 may mediate the efficient recruitment of SOX2 
to its targets, mediating rapid expression of SOX2 target factors upon exit from the 
quiescent state. In line with this, MYEF2 expression is not reduced in vitro when 
treating with BMP4 and Myef2 knockout cells are potentially less efficient at exiting 
the quiescent state, though further experiments, such as epigenetic profiling, are 
required to confirm this. Targeting quiescent CSCs, which are considered responsible 
for tumour relapse after surgery, radiotherapy and chemotherapy6–9, is an attractive 
therapy. If the core molecules and signals involved in the exit from quiescence can 
be identified, it may be possible to inhibit cells from waking up, making tumour 
recurrence is unlikely. 
 
The second hypothesis is that MYEF2 is functioning as a splicing factor mediating the 
rapid and correct co-transcriptional splicing286 of SOX2 target genes. In line with this, 
our mass spectrometry data of MYEF2 interactors was enriched with interactors 
associated with mRNA processing and splicing, and others have shown mRNA 
binding of MYEF2275,276. Additionally, MYEF2 does not act as bookmarking factor and 
dissociated from the mitotic chromatin, and possibly SOX2, during mitosis. It should 
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be noted that during mitosis, transcription is reduced on a global scale287 hence, 
MYEF2 target mRNAs may not be present. Finally levels of MYEF2, and many other 
RNA binding proteins, are high in both the brain and testis, the two tissues associated 
with highest levels of alternative splicing288,289. In support of a potential RNA splicing 
mechanism, there is growing evidence indicating that alterations in RNA splicing play 
tumorigenic roles, with global splicing changes and mutations in several splicing 
factors observed in multiple types of cancer290–292. Furthermore, the inhibition of 
arginine methyltransferase PRMT5 can alter the splicing of detained introns and 
mediate suppression of in vivo GBM tumour growth 293. 
 
To distinguish between these mechanisms, and understand the biology, several 
experiments could be performed. RNA-seq in lines with and without MYEF2 should 
allow us to look at alternative splicing of transcripts. If we were to observe a clear 
enrichment in alternative splicing of transcripts from genes regulated by SOX2, this 
would support that MYEF2 functions as a splicing factor. ChIP-seq would allow 
assessment of the overlap of MYEF2 and SOX2, and help to asses if MYEF2 does 
enable the rapid recruitment of SOX2 to its G1 targets upon re-entry to the cell cycle. 
In addition, if MYEF2 is a splicing factor binding would be enriched over exon-intron 
boundaries. Finally, RNA immunoprecipitation methods, such as RIP and CLIP294, 
coupled with sequencing can identify the exact RNAs bound to MYEF2, hence 
providing potential explanation for the observed Myef2 knockout phenotype. 
 
The proposed mechanisms of MYEF2 functioning as an RNA binding protein are likely 
to make it difficult to directly therapeutically target. Some proposed methods for 
therapeutically targeting splicing295, including splice-switch oligonucleotides and 
spliceosome inhibitors, do exist however they are not well established, though 
alternatively, the transcripts and corresponding proteins which are altered by 
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alternative splicing could be therapeutically targeted. The combination of the strength 
of the phenotype observed in Myef2 knockouts and the difficulty in targeting an RNA 
binding protein, mean it is unlikely one would invest in MYEF2 alone as a therapeutic 
candidate. Whilst this may be the case, understanding the interplay of SOX2 and 
MYEF2 is likely to providing exciting insight into the fundamental behaviour of SOX2 
and RNA biology. 
 
Whilst disrupting NSC, or more ideally GSC, specific SOX2 interactors is a potential 
therapeutic approach, the SOX2 interactors responsible for key functions of SOX2 are 
yet to be identified and it is possible that many interactors of SOX2, like MYEF2, will 
individually only mildly effect SOX2’s function. Hence, it is important that other 
avenues for targeting SOX2 are explored, including exploration of the effects of post-
translational modifications, and the upstream signalling responsible, on SOX2125. 
 
6.2 The SMASh degron is successful at modulation of the nuclear 
protein SOX2 in NSCs 
Conditional degrons provide alternative methods to classical genetic gene knockout 
and siRNA knockdowns, to study a proteins role through loss of function studies. 
Many conditional degrons exist, each with different features including those such as 
sensitivity to light or control by small molecules. Of particular interest, is the relatively 
recently derived SMASh tag degron224. Unlike many other degrons, the rate of 
degradation is dependent on the half-life of the protein and hence slow. However, the 
SMASh degron has the key advantages of easy dose dependant response and most 
importantly, the protein of interest (POI) to which it is fused is left minimally modified. 
This feature is especially important if the POI has known functional domains at the N- 
or C-terminal, as the addition of tags may affect protein function. In this thesis I 
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describe the successful use of the SMASh tag degron to control the protein levels of 
exogenous and endogenous SOX2 within mouse NSCs.  
 
From the expression of exogenous SOX2-mCherry-SMASh we observed a clear dose 
dependant reduction in SOX2-mCherry levels. A maximal ~90% reduction in protein 
could observed in response to 1µM HCV N3S protease inhibitor ASV. At a slight lower 
rate than transgene, endogenously tagged SOX2-mCherry-SMASh was depleted to 
20% of the endogenous level. This reduction was slow to achieve, taking 48hrs, due 
to the dependence on the proteins half-life. The absence of bi-allelic knock in clones 
has hampered the ability to test if this 80% knockdown is sufficient to investigate the 
phenotypic effects of SOX2 loss. Ongoing attempts are underway to derive a bi-allelic 
SMASh knock-in clones within NSCs and GSCs. Once obtained, bi-allelic SMASh 
tagged lines should allow both in vitro and in vivo experimentation in order to model 
the effects that the loss of SOX2 has on proliferation, senescence, BMP sensitivity, 
clonogenicity and on tumour initiation and maintenance. This approach will allow for 
rigorous evaluation of the function of SOX2, and the effect of varying SOX2 levels, in 
GBM, without the off-target effects associated with siRNA and CRISPR of previous 
studies. 
 
The SMASh tag appears to act on a wide range of proteins224,263,264,266. This versatile 
degron may provide an excellent tool for further investigations of the function of myef2. 
In particular the generation of a bi-allelic Myef2-SMASh knock-in may complement 
knockout experiments and provide an alternative to the requirement of MYEF2 rescue 
experiments as described in chapter 4. Using endogenously tagged Myef2-SMASh 
assays can be performed in the exact same line in the absence and presence of ASV. 
Use of a control untagged line in the presence of ASV can account for any phenotypic 
observations by ASV. This alternative can avoid several of the issues associated with 
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piggyBac rescue experiments including non-physiological protein expression levels 
and limited isoform expression.   
 
While the SMASh degron has the distinct advantage of leaving the protein of interest 
minimally modified, hence minimising the chance of altering normal protein functions, 
new degrons are continually being identified and developed, and current ones 
improved, expanding the repertoire of the degron toolbox. For example, the AID 
system has recently been improved through the development of mini-AID (mAID), a 
68 aa fragment of the original 229 aa long AID296, and improvements are being made 
to improve the leaky degradation often observed with the AID system297–299. Many of 
the degrons developed require the genetic modification of the protein of interest, 
providing a valuable research tool but are unsuitable for direct therapeutic use in 
patients. An exception to this are proteolysis-targeting chimeric molecules 
(PROTACs), which do not require modification of the target protein but change the 
specificity of E3 ligases (induce polyubiquitylation and proteasomal degradation) by 
tethering the protein of interest to an E3 ligase. As PROTACs are specific, they must 
be identified for each protein of interest and at the time of writing this thesis we were 
not aware of any that are capable of targeting SOX2, however it is clear that 
PROTACs are a potentially viable method to clinically degrade transcription factors, 
such as SOX2, which were previously considered “undruggable”300–302. 
 
6.3 Concluding remarks 
To conclude, the RNA binding protein MYEF2 is pro-tumorigenic in GSCs, and most 
likely operates with SOX2. Dissecting the functions and mechanism of MYEF2 should 
expand our understanding of SOX2. The SMASh tag, combined with the efficiency of 
CRISPR/Cas9 genome editing, should provide a key tool for therapeutic target 
validation and support drug discovery efforts. 
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Chapter 7 Appendix 
7.1 List of ssODN, targeting vectors and piggyBac plasmids  









































   






































   








• TRE3G  
• Myef2 (isoform 201) plus C terminal HA tag 
• IRES 










• Sox2-mCherry  
• IRES 
• Puromycin 
   























• 500bp homology arms 
• Sox2-mCherry-SMASh 
   
























• 500bp homology arms 
• Sox2-HA-SMASh-P2A-mCherry 
 
Table 8: List of ssODN, targeting vectors and piggyBac plasmids used  
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7.2 Protein interactors of MYEF2-HA identified by mass spectrometry 
Gene.names Q.value Score log2.av.ratio gm.pval 
A0A140T8P5 0 92.4790 11.4440 0.0124 
Myef2 0 323.3100 8.9526 0.0087 
Rsrc2 0 68.6730 8.9341 0.0379 
Rab3b 0 22.3760 7.8571 0.0236 
Snip1 0 70.3630 6.2991 0.0149 
Fam64a 0 16.9570 6.2912 0.0011 
Dido1 0 3.9610 6.2731 0.0004 
Ddx46 0 323.3100 6.2113 0.0136 
Ahcyl2 0.0014058 3.0926 6.1672 0.0021 
Naca 0.0041247 2.8036 5.9168 0.0038 
Rsrc1 0 67.7650 5.7752 0.0062 
Gldc 0 3.9697 5.6515 0.0356 
Mmtag2 0 86.1790 5.6004 0.0272 
Rab3a 0 16.0050 5.5660 0.0020 
Tnrc6a 0 32.0450 5.3826 0.0005 
Rab7a 0.00048239 3.4820 5.2746 0.0004 
Ighv1-18 1 -2.0000 5.2676 0.0015 
Ctsc 0 19.2890 5.2540 0.0020 
Rfx4 0 14.5560 5.1448 0.0048 
Rrm1 0.0027701 2.9195 5.1393 0.0005 
Tfrc 0 157.7200 5.0252 0.0001 
Sf3b6 0 29.1720 5.0170 0.0417 
Dock10 0 5.2659 5.0047 0.0048 
Hnrnph3 0 27.4220 4.8105 0.0012 
Zcchc6 0 5.8302 4.8095 0.0020 
Ide 0 169.4200 4.7995 0.0107 
Olfm2 0 8.5537 4.7198 0.0014 
Tmed10 0.0071652 2.4774 4.5463 0.0015 
AU019823 0 44.6830 4.5299 0.0128 
Taf2 0 323.3100 4.4166 0.0432 
Commd6 0 5.4391 4.2750 0.0017 
Hnrnpm 0 323.3100 4.0639 0.0004 
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Rbm39 0 323.3100 3.8430 0.0395 
S100a13 0 11.8060 3.7567 0.0194 
Nudt21 0 112.4800 3.7337 0.0033 
Hexim1 0 173.5400 3.7332 0.0318 
Scaf11 0 100.9100 3.5904 0.0431 
Rtn1 0.0079752 2.4003 3.5804 0.0090 
Fip1l1 0 284.5400 3.5256 0.0136 
Cpsf1 0 268.3100 3.3915 0.0177 
Nusap1 0 72.1200 3.3740 0.0346 
Ncan 0 262.5400 3.3264 0.0322 
Apobec1 0 32.5530 3.1330 0.0144 
Wdr33 0 215.9800 3.0568 0.0087 
Cactin 0 132.1500 2.9973 0.0415 
U2af1l4 0 120.5600 2.9956 0.0285 
Cdk13 0 230.8500 2.8650 0.0394 
Snrnp27 0 124.2800 2.8180 0.0252 
Srek1ip1 0 17.5310 2.7664 0.0343 
Cpsf2 0 149.4000 2.7262 0.0168 
Marcks 0 11.8360 2.7237 0.0022 
Sf3b1 0 323.3100 2.6808 0.0003 
Zrsr1 0 9.3144 2.6761 0.0088 
Surf6 0 15.6150 2.5916 0.0475 
Mlf2 0 37.5790 2.5685 0.0170 
Rpl29;Gm1766
9;Gm3550 
0 43.6430 2.5385 0.0486 
Rbm3 0 27.6520 2.5370 0.0128 
Riok2 0 15.8520 2.5367 0.0028 
Map2 0 45.4580 2.4893 0.0000 
Nol12 0 33.6890 2.4524 0.0261 
Cpsf3 0 173.4500 2.4266 0.0141 
Mark3 0 32.3970 2.4186 0.0260 
Sf1 0 22.2500 2.4161 0.0303 
Prkcb 0 54.9540 2.4142 0.0014 
Pcbp1 0 323.3100 2.3792 0.0184 
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Mrpl38 0 109.9100 2.3212 0.0377 
Calu 0 123.9300 2.3122 0.0166 
Cpsf7 0 50.7140 2.2404 0.0039 
Sap30bp 0 29.7260 2.2385 0.0038 
Ahcyl1 0 34.2660 2.2004 0.0069 
Rbm7 0 29.6210 2.1350 0.0308 
Hmgxb4 0 26.5050 2.0897 0.0394 
Vav3 0 112.0300 2.0781 0.0114 
Hnrnpd 0 73.2870 2.0638 0.0011 
Cluh 0 25.7090 2.0232 0.0310 
Sox2 0 170.9200 2.0123 0.0222 
 
Table 9: Protein interactors of MYEF2-HA by mass spectrometry 
 
